2001

U.S. Food and Drug Administration Grants 510k Clearance For Specialized Health Products' Safety Huber Needle Infusion Set: Business Wire - December 17, 2001; BOUNTIFUL, Utah--Specialized Health Products(R) International, Inc. (OTCBB: SHPI), a leader in the design and development of medical safety needles, today announced its wholly-owned subsidiary, Safety Syringe Corporation, has received 510(k) clearance from the U.S. Food and Drug Administration ( FDA ) to marke
TherapyEdge Debuts Flagship Product "TherapyEdge HIV": Business Wire - December 17, 2001; CHICAGO--Web-based, Point-of-Care, Decision-Support System to Assist Clinicians Treating HIV; System Delivers Therapy Options, Based on Patient Data and the Latest Clinical Research TherapyEdge(TM), Inc., developer and provider of cutting-edge, point-of-care decision support systems for individualized patient care, tod
HIV Entry Inhibitors Featured in Keynote Session At Major Scientific Meeting; Fusion Inhibitors T-20 and T-1249, Furthest in Clinical Development, Among Those Discussed: Business Wire - December 17, 2001; CHICAGO--Responding to the need for HIV treatments that work against the virus in a new way, scientists and clinicians are gathering this week at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), being held here December 16-19, 2001, to review the latest research on entry inhibitors.
Specialty Laboratories and VIRalliance Introduce Phenoscript, Assay for Identifying Resistance to HIV Therapy: Business Wire -December 13,2001; SANTA MONICA, Calif. & PARIS--Specialty Expands its Comprehensive Suite of HIV Testing to Become First Full Service Laboratory Offering In-House Phenotyping Specialty Laboratories, Inc. (NYSE:SP) (Specialty), a leading research-driven clinical reference laboratory, and VIRalliance, a subsidiary of BioAlliance, The
US's Largest AIDS Group Launches Africa AIDS Treatment Initiative; Goal: Provide Access to Life-Saving Care in Hard-Hit African Country: Business Wire - December 6, 2001; LOS ANGELES--(BW HealthWire)--The Ministry of Health/Government of Uganda , the Ugandan Business Coalition on HIV/AIDS and AIDS Healthcare Foundation Global Immunity Join Forces in Uganda Cares, a New AIDS Treatment Initiative AHF Global Community (AHF GI), an international initiative of AIDS Healthcare Foundation, tod
United States Military Sponsored Research On Hemispherx Biopharma's Immune-Based Approach to Bioterrorism -- Smallpox -- Shows Promise: Business Wire - December 6, 2001; PHILADELPHIA -- Independent Research Also Suggests Serious Side Effects Of Smallpox Vaccine May Also Be Reduced; Company Continuing Advanced Clinical Trials in HIV/AIDS And Chronic Fatigue Syndrome Hemispherx Biopharma, Inc. (AMEX:HEB), a leading company in the development of immune based therapies primarily addressing
International Organization to Deliver Centra-Powered Web Conference on HIV Treatment: Business Wire - December 3,2001; LEXINGTON, Mass. -- International Association of Physicians in AIDS Care Presents Overview of Treatment Paradigm Shift Signaled by the Latest Revisions of the DHHS Guidelines Centra (NASDAQ: CTRA), the leading provider of software infrastructure and ASP services for eLearning and real-time business collaboration, today
Immune Network Announces InNexus 'SuperAntibody' Collaboration: Business Wire - December 3, 2001; VANCOUVER, B.C.-- Immune Network Ltd. (OTCBB:IMMKF)(CDNX:IMM) announced today it has granted a sublicense option to InNexus Corporation of Seattle for the application of SuperAntibody technology to Immune Network s monoclonal antibodies hNM01 and 1F7. InNexus is focused on the use of SuperAntibodies, a new technology t
UN Secretary General Delivers Major "World AIDS Day" Address In Waldorf Astoria Luncheon: Business Wire - November 30, 2001; NEW YORK -- Luncheon Honors UK Physician Dame Cicely Saunders and St. Christopher s Hospice Recipient of 2001 Hilton Humanitarian Prize At an award luncheon that was Web cast live (video and audio) from the Hilton Web site www.hiltonfoundation.org, UN Secretary General Kofi Annan called for an expansion of hospice worl
Yahoo! and IAVI get message out about World Aids Day; Yahoo! Messenger IMVironment and Promotion Help Gather Signatures to Raise Global Support for AIDS Vaccine Research: Business Wire - November 29, 2001; SUNNYVALE, Calif. and NEW YORK--(BUSINESS WIRE)--Nov. 29, 2001-- When people log onto Yahoo!(R) Messenger (http://messenger.yahoo.com) during December, they can help in the global effort to find a vaccine for AIDS. As part of worldwide recognition of World AIDS Day on December 1, Yahoo! Inc. (Nasdaq:YHOO), a leading gl
Yahoo! and IAVI get message out about World Aids Day; Yahoo! Messenger IMVironment and Promotion Help Gather Signatures to Raise Global Support for AIDS Vaccine Research: Business Wire - November 29, 2001; SUNNYVALE, Calif. and NEW YORK--(BUSINESS WIRE)--Nov. 29, 2001-- When people log onto Yahoo!(R) Messenger (http://messenger.yahoo.com) during December, they can help in the global effort to find a vaccine for AIDS. As part of worldwide recognition of World AIDS Day on December 1, Yahoo! Inc. (Nasdaq:YHOO), a leading gl
Amerimmune Completes Phase Ia Human Safety Trial for Monoclonal Antibody HIV Treatment: Business Wire - November 29, 2001; WOODLAND HILLS, Calif.--(BW HealthWire)--Nov. 29, 2001--Amerimmune Pharmaceuticals Inc. (OTCBB:AMUN), a pharmaceutical research company that is developing Cytolin(R), a revolutionary treatment for patients suffering from human immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS), today announced
Amerimmune Completes Phase Ia Human Safety Trial for Monoclonal Antibody HIV Treatment: Business Wire - November 29, 2001; WOODLAND HILLS, Calif.--(BW HealthWire)--Nov. 29, 2001--Amerimmune Pharmaceuticals Inc. (OTCBB:AMUN), a pharmaceutical research company that is developing Cytolin(R), a revolutionary treatment for patients suffering from human immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS), today announced
Calypte Biomedical Signs Key Agreement to Develop New Urine-based Test; Will Diagnose HIV Infection in as Little as 15 Minutes: Business Wire - November 23, 2001; ALAMEDA, Calif.--(BW HealthWire)--Nov. 23, 2001--Calypte Biomedical Corp. (OTCBB:CALY) today announced it has signed a key agreement with San Antonio-based SA Scientific Inc., a privately held company, to develop a new urine-based rapid HIV-1/2 antibody test that can provide results in as little as 15 minutes. Our expa
Calypte Biomedical Signs Key Agreement to Develop New Urine-based Test; Will Diagnose HIV Infection in as Little as 15 Minutes: Business Wire - November 23, 2001; ALAMEDA, Calif.--(BW HealthWire)--Nov. 23, 2001--Calypte Biomedical Corp. (OTCBB:CALY) today announced it has signed a key agreement with San Antonio-based SA Scientific Inc., a privately held company, to develop a new urine-based rapid HIV-1/2 antibody test that can provide results in as little as 15 minutes. Our expa
Calypte Biomedical Signs Key Agreement to Develop New Urine-based Test; Will Diagnose HIV Infection in as Little as 15 Minutes: Business Wire - November 23, 2001; ALAMEDA, Calif.--(BW HealthWire)--Nov. 23, 2001--Calypte Biomedical Corp. (OTCBB:CALY) today announced it has signed a key agreement with San Antonio-based SA Scientific Inc., a privately held company, to develop a new urine-based rapid HIV-1/2 antibody test that can provide results in as little as 15 minutes. Our expa
Genesis Technology Group's Subsidiary Signs Agreement for Exclusive Distribution of Hepatitis B Product in China: Business Wire - November 20, 2001; WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 20, 2001--Genesis Technology Group, Inc. (OTCBB:GTEC) announced today that its subsidiary, Biosystems Technologies, Inc., has signed an exclusive agreement for clinical trials and distribution of a new herbal product believed to be effective in the treatment of viral Hepatit
Genesis Technology Group's Subsidiary Signs Agreement for Exclusive Distribution of Hepatitis B Product in China: Business Wire - November 20, 2001; WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 20, 2001--Genesis Technology Group, Inc. (OTCBB:GTEC) announced today that its subsidiary, Biosystems Technologies, Inc., has signed an exclusive agreement for clinical trials and distribution of a new herbal product believed to be effective in the treatment of viral Hepatit
Genesis Technology Group's Subsidiary Signs Agreement for Exclusive Distribution of Hepatitis B Product in China: Business Wire - November 20, 2001; WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 20, 2001--Genesis Technology Group, Inc. (OTCBB:GTEC) announced today that its subsidiary, Biosystems Technologies, Inc., has signed an exclusive agreement for clinical trials and distribution of a new herbal product believed to be effective in the treatment of viral Hepatit
ViaLogy Corp. Issued Third U.S. Patent Covering Technique for Determining Viral Load Using Microarrays: Business Wire - November 15, 2001; PASADENA, Calif.--(BW HealthWire)--Nov. 15, 2001--ViaLogy Corp. today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 6,245,511, titled Method and Apparatus for Exponentially Convergent Therapy Effectiveness Monitoring Using DNA Microarray-Based Viral Load Measurements, which has been assigne
ViaLogy Corp. Issued Third U.S. Patent Covering Technique for Determining Viral Load Using Microarrays: Business Wire - November 15, 2001; PASADENA, Calif.--(BW HealthWire)--Nov. 15, 2001--ViaLogy Corp. today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 6,245,511, titled Method and Apparatus for Exponentially Convergent Therapy Effectiveness Monitoring Using DNA Microarray-Based Viral Load Measurements, which has been assigne
ViaLogy Corp. Issued Third U.S. Patent Covering Technique for Determining Viral Load Using Microarrays: Business Wire - November 15, 2001; PASADENA, Calif.--(BW HealthWire)--Nov. 15, 2001--ViaLogy Corp. today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 6,245,511, titled Method and Apparatus for Exponentially Convergent Therapy Effectiveness Monitoring Using DNA Microarray-Based Viral Load Measurements, which has been assigne
Planned Parenthood Mar Monte to Offer Calypte's Urine HIV-1 Antibody Tests: Business Wire - November 14, 2001; ALAMEDA, Calif.--(BW HealthWire)--Nov. 14, 2001--Calypte Biomedical Corporation (OTCBB:CALY) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organiz
Planned Parenthood Mar Monte to Offer Calypte's Urine HIV-1 Antibody Tests: Business Wire - November 14, 2001; ALAMEDA, Calif.--(BW HealthWire)--Nov. 14, 2001--Calypte Biomedical Corporation (OTCBB:CALY) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organiz
Planned Parenthood Mar Monte to Offer Calypte's Urine HIV-1 Antibody Tests: Business Wire - November 14, 2001; ALAMEDA, Calif.--(BW HealthWire)--Nov. 14, 2001--Calypte Biomedical Corporation (OTCBB:CALY) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organiz
Planned Parenthood Mar Monte to Offer Calypte's Urine HIV-1 Antibody Tests: Business Wire - November 14, 2001; ALAMEDA, Calif. -- Calypte Biomedical Corporation (OTCBB:CALY) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organization, has the only CLIA-appro
Planned Parenthood Mar Monte to Offer Calypte's Urine HIV-1 Antibody Tests: Business Wire - November 14, 2001; ALAMEDA, Calif. -- Calypte Biomedical Corporation (OTCBB:CALY) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organization, has the only CLIA-appro
Planned Parenthood Mar Monte to Offer Calypte's Urine HIV-1 Antibody Tests: Business Wire - November 14, 2001; ALAMEDA, Calif. -- Calypte Biomedical Corporation (OTCBB:CALY) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organization, has the only CLIA-appro
Scott-Levin Announces Disease Management Policy Alerts: How and When States Look to Control Drug Costs for Chronic Conditions: Business Wire - November 14, 2001; NEWTOWN, Pa.-- State government officials see pharmaceutical spending for chronic diseases as an opportunity to control health care costs. Disease Management Policy Alerts, designed to provide a detailed look at state programs, legislation and regulations affecting chronic diseases, has been launched by Scott-Levin, a
Scott-Levin Announces Disease Management Policy Alerts: How and When States Look to Control Drug Costs for Chronic Conditions: Business Wire - November 14, 2001; NEWTOWN, Pa.-- State government officials see pharmaceutical spending for chronic diseases as an opportunity to control health care costs. Disease Management Policy Alerts, designed to provide a detailed look at state programs, legislation and regulations affecting chronic diseases, has been launched by Scott-Levin, a
Scott-Levin Announces Disease Management Policy Alerts: How and When States Look to Control Drug Costs for Chronic Conditions: Business Wire - November 14, 2001; NEWTOWN, Pa.-- State government officials see pharmaceutical spending for chronic diseases as an opportunity to control health care costs. Disease Management Policy Alerts, designed to provide a detailed look at state programs, legislation and regulations affecting chronic diseases, has been launched by Scott-Levin, a
Bastyr University's Leading Researcher is Co-editor & Author of New AIDS Book; Harcourt Releases AIDS And Complementary Alternative Therapy: Business Wire - November 13, 2001; KENMORE, Wash.--(BUSNESS WIRE)--Nov. 13, 2001--Leanna Standish, ND, PhD, LAc, Senior Research Scientist at Bastyr University s Research Institute, is co-editor of a new book from Harcourt International about treating AIDS with complementary and alternative medicine (CAM). AIDS and Complementary and Alternative Therapy
Bastyr University's Leading Researcher is Co-editor & Author of New AIDS Book; Harcourt Releases AIDS And Complementary Alternative Therapy: Business Wire - November 13, 2001; KENMORE, Wash.--(BUSNESS WIRE)--Nov. 13, 2001--Leanna Standish, ND, PhD, LAc, Senior Research Scientist at Bastyr University s Research Institute, is co-editor of a new book from Harcourt International about treating AIDS with complementary and alternative medicine (CAM). AIDS and Complementary and Alternative Therapy
Bastyr University's Leading Researcher is Co-editor & Author of New AIDS Book; Harcourt Releases AIDS And Complementary Alternative Therapy: Business Wire - November 13, 2001; KENMORE, Wash.--(BUSNESS WIRE)--Nov. 13, 2001--Leanna Standish, ND, PhD, LAc, Senior Research Scientist at Bastyr University s Research Institute, is co-editor of a new book from Harcourt International about treating AIDS with complementary and alternative medicine (CAM). AIDS and Complementary and Alternative Therapy
Enzo Biochem Announces Plans to Initiate Double-Blind Study of Hepatitis B EHT899 Medicine: Presentation at Dallas Meeting of Liver Specialists Details Successful Phase 2 Study Results Relating to Reduced Key Inflammatory Scores: Business Wire - November 12 ,2001; Enzo Biochem, Inc. (NYSE:ENZ), encouraged by results thus far of its Phase 2 study of EHT899, the Company s proprietary medicine for treating patients suffering from chronic active hepatitis associated with hepatitis B virus ( HBV ), said it is planning to launch a multi-centered, double blind, randomized study of the
Enzo Biochem Announces Plans to Initiate Double-Blind Study of Hepatitis B EHT899 Medicine: Presentation at Dallas Meeting of Liver Specialists Details Successful Phase 2 Study Results Relating to Reduced Key Inflammatory Scores: Business Wire - November 12 ,2001; Enzo Biochem, Inc. (NYSE:ENZ), encouraged by results thus far of its Phase 2 study of EHT899, the Company s proprietary medicine for treating patients suffering from chronic active hepatitis associated with hepatitis B virus ( HBV ), said it is planning to launch a multi-centered, double blind, randomized study of the
Enzo Biochem Announces Plans to Initiate Double-Blind Study of Hepatitis B EHT899 Medicine: Presentation at Dallas Meeting of Liver Specialists Details Successful Phase 2 Study Results Relating to Reduced Key Inflammatory Scores: Business Wire - November 12 ,2001; Enzo Biochem, Inc. (NYSE:ENZ), encouraged by results thus far of its Phase 2 study of EHT899, the Company s proprietary medicine for treating patients suffering from chronic active hepatitis associated with hepatitis B virus ( HBV ), said it is planning to launch a multi-centered, double blind, randomized study of the
ViroPharma and Wyeth-Ayerst Provide Update on Hepatitis C Program: Business Wire - November 12, 2001; EXTON, Pa.--(BUSINESS WIRE)--Nov. 12, 2001--ViroPharma Incorporated and Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products Corporation , today announced an update regarding their collaboration to develop treatments for hepatitis C. The companies are engaged in a broad-based discovery resea
ViroPharma and Wyeth-Ayerst Provide Update on Hepatitis C Program: Business Wire - November 12, 2001; EXTON, Pa.--(BUSINESS WIRE)--Nov. 12, 2001--ViroPharma Incorporated and Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products Corporation , today announced an update regarding their collaboration to develop treatments for hepatitis C. The companies are engaged in a broad-based discovery resea
ViroPharma and Wyeth-Ayerst Provide Update on Hepatitis C Program: Business Wire - November 12, 2001; EXTON, Pa.--(BUSINESS WIRE)--Nov. 12, 2001--ViroPharma Incorporated and Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products Corporation , today announced an update regarding their collaboration to develop treatments for hepatitis C . The companies are engaged in a broad-based discovery r
AIDS Healthcare Foundation Signs Pharmacy Management Services Contract with R & K Pharmacy Services, Inc.; R & K To Provide Services to AHF Patients in Florida: Business Wire - November 7, 2001; LOS ANGELES--(BUSINESS WIRE)--Nov. 7, 2001--AIDS Healthcare Foundation (AHF), the nation s largest private provider of HIV medical services, announced today that it signed a contract with R & K Pharmacy Services, Inc., an affiliate of Metropolitan Health Networks, Inc., for R & K to provide pharmacy management
AIDS Healthcare Foundation Signs Pharmacy Management Services Contract with R & K Pharmacy Services, Inc.; R & K To Provide Services to AHF Patients in Florida: Business Wire - November 7, 2001; LOS ANGELES--(BUSINESS WIRE)--Nov. 7, 2001--AIDS Healthcare Foundation (AHF), the nation s largest private provider of HIV medical services, announced today that it signed a contract with R & K Pharmacy Services, Inc., an affiliate of Metropolitan Health Networks, Inc., for R & K to provide pharmacy management
AIDS Healthcare Foundation Signs Pharmacy Management Services Contract with R & K Pharmacy Services, Inc.; R & K To Provide Services to AHF Patients in Florida: Business Wire - November 7, 2001; LOS ANGELES--(BUSINESS WIRE)--Nov. 7, 2001--AIDS Healthcare Foundation (AHF), the nation s largest private provider of HIV medical services, announced today that it signed a contract with R & K Pharmacy Services, Inc., an affiliate of Metropolitan Health Networks, Inc., for R & K to provide pharmacy management
NHI Launches Bioterror Medical Alert, a Twice-monthly Source of News and Guidance for Doctors and Other Healthcare Professionals: Business Wire - November 7, 2001; ATLANTA--(BW HealthWire)--Nov. 7, 2001--Atlanta-based National Health Information, LLC, one of the country s leading healthcare publishers, today announced the launch of Bioterror Medical Alert, a twice-monthly newsletter providing doctors and other health professionals with up-to-the-minute news and guidance on the cl
NHI Launches Bioterror Medical Alert, a Twice-monthly Source of News and Guidance for Doctors and Other Healthcare Professionals: Business Wire - November 7, 2001; ATLANTA--(BW HealthWire)--Nov. 7, 2001--Atlanta-based National Health Information, LLC, one of the country s leading healthcare publishers, today announced the launch of Bioterror Medical Alert, a twice-monthly newsletter providing doctors and other health professionals with up-to-the-minute news and guidance on the cl
NHI Launches Bioterror Medical Alert, a Twice-monthly Source of News and Guidance for Doctors and Other Healthcare Professionals: Business Wire - November 7, 2001; ATLANTA--(BW HealthWire)--Nov. 7, 2001--Atlanta-based National Health Information, LLC, one of the country s leading healthcare publishers, today announced the launch of Bioterror Medical Alert, a twice-monthly newsletter providing doctors and other health professionals with up-to-the-minute news and guidance on the cl
Roche and Trimeris Announce Plans for Enrollment In T-20 Open-Label Study; Companies Inform U.S. Physicians of Enrollment Process: Business Wire - November 7, 2001; NUTLEY, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2001--Roche and Trimeris (Nasdaq: TRMS) today announced that site selection and patient enrollment will begin in the U.S. for T20-305, an open-label study of the investigational HIV drug T-20 in combination with oral antiretrovirals that will be conducted in Nor
Roche and Trimeris Announce Plans for Enrollment In T-20 Open-Label Study; Companies Inform U.S. Physicians of Enrollment Process: Business Wire - November 7, 2001; NUTLEY, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2001--Roche and Trimeris (Nasdaq: TRMS) today announced that site selection and patient enrollment will begin in the U.S. for T20-305, an open-label study of the investigational HIV drug T-20 in combination with oral antiretrovirals that will be conducted in Nor
Roche and Trimeris Announce Plans for Enrollment In T-20 Open-Label Study; Companies Inform U.S. Physicians of Enrollment Process: Business Wire - November 7, 2001; NUTLEY, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2001--Roche and Trimeris (Nasdaq: TRMS) today announced that site selection and patient enrollment will begin in the U.S. for T20-305, an open-label study of the investigational HIV drug T-20 in combination with oral antiretrovirals that will be conducted in Nor
A Majority Of Physicians Now Turning To The Internet For Congress News On Medical Advances And Developments Says Nuvis Worldwide: Business Wire - November 5, 2001; MONTREAL--(BW HealthWire)--Nov. 6, 2001--More than two thirds of the eleven thousand physicians participating in a recent survey said they rely on Internet and/or e-mail medical news services to keep abreast of developments emanating from medical conferences and other large medical meetings they do not attend. Nuvis Wo
A Majority Of Physicians Now Turning To The Internet For Congress News On Medical Advances And Developments Says Nuvis Worldwide: Business Wire - November 5, 2001; MONTREAL--(BW HealthWire)--Nov. 6, 2001--More than two thirds of the eleven thousand physicians participating in a recent survey said they rely on Internet and/or e-mail medical news services to keep abreast of developments emanating from medical conferences and other large medical meetings they do not attend. Nuvis Wo
A Majority Of Physicians Now Turning To The Internet For Congress News On Medical Advances And Developments Says Nuvis Worldwide: Business Wire - November 5, 2001; MONTREAL--(BW HealthWire)--Nov. 6, 2001--More than two thirds of the eleven thousand physicians participating in a recent survey said they rely on Internet and/or e-mail medical news services to keep abreast of developments emanating from medical conferences and other large medical meetings they do not attend. Nuvis Wo
METCARE Awarded Exclusive Contract for Pharmacy Management Services with Nation's Largest HIV / AIDS Medical Provider: Projected Revenues of $105 Million in 2002 and $240 Million in 2003: Business Wire - November 5, 2001; WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 5, 2001-- AIDS Healthcare Foundation Clinic Patients to Benefit from On-site Pharmacy Services: Patient-focused Program Aims to Boost Adherence to Medication Regimens Metropolitan Health Networks, Inc. (METCARE(TM))(OTC BB: MDPA) today announced that its pharmacy division, M
METCARE Awarded Exclusive Contract for Pharmacy Management Services with Nation's Largest HIV / AIDS Medical Provider: Projected Revenues of $105 Million in 2002 and $240 Million in 2003: Business Wire - November 5, 2001; WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 5, 2001-- AIDS Healthcare Foundation Clinic Patients to Benefit from On-site Pharmacy Services: Patient-focused Program Aims to Boost Adherence to Medication Regimens Metropolitan Health Networks, Inc. (METCARE(TM))(OTC BB: MDPA) today announced that its pharmacy division, M
METCARE Awarded Exclusive Contract for Pharmacy Management Services with Nation's Largest HIV / AIDS Medical Provider: Projected Revenues of $105 Million in 2002 and $240 Million in 2003: Business Wire - November 5, 2001; WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 5, 2001-- AIDS Healthcare Foundation Clinic Patients to Benefit from On-site Pharmacy Services: Patient-focused Program Aims to Boost Adherence to Medication Regimens Metropolitan Health Networks, Inc. (METCARE(TM))(OTC BB: MDPA) today announced that its pharmacy division, M
Panel of Distinguished Scientific Consultants Assists Amerimmune in Development of Monoclonal Antibody for Treatment of HIV: Business Wire - November 01, 2001; WOODLAND HILLS, Calif.--(BW HealthWire)--Nov. 1, 2001--Amerimmune Pharmaceuticals Inc. (OTCBB:AMUN), a pharmaceutical research company that is developing Cytolin(R), a revolutionary treatment for patients suffering from human immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS), today announced t
Panel of Distinguished Scientific Consultants Assists Amerimmune in Development of Monoclonal Antibody for Treatment of HIV: Business Wire - November 01, 2001; WOODLAND HILLS, Calif.--(BW HealthWire)--Nov. 1, 2001--Amerimmune Pharmaceuticals Inc. (OTCBB:AMUN), a pharmaceutical research company that is developing Cytolin(R), a revolutionary treatment for patients suffering from human immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS), today announced t
Panel of Distinguished Scientific Consultants Assists Amerimmune in Development of Monoclonal Antibody for Treatment of HIV: Business Wire - November 01, 2001; WOODLAND HILLS, Calif.--(BW HealthWire)--Nov. 1, 2001--Amerimmune Pharmaceuticals Inc. (OTCBB:AMUN), a pharmaceutical research company that is developing Cytolin(R), a revolutionary treatment for patients suffering from human immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS), today announced t
Genesis Technology Group, Inc. Partners with Prominent Immunology Researcher to Form Biotechnology Subsidiary: Business Wire - OCT 30, 2001; WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Oct. 30, 2001--Genesis Technology Group, Inc. (OTCBB:GTEC) announced today that it has formed a subsidiary to enter into the biotechnology marketplace. The new company, Biosystems Technologies, Inc. is engaged in the commercialization, marketing and distribution of biomedical pro
Genesis Technology Group, Inc. Partners with Prominent Immunology Researcher to Form Biotechnology Subsidiary: Business Wire - OCT 30, 2001; WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Oct. 30, 2001--Genesis Technology Group, Inc. (OTCBB:GTEC) announced today that it has formed a subsidiary to enter into the biotechnology marketplace. The new company, Biosystems Technologies, Inc. is engaged in the commercialization, marketing and distribution of biomedical pro
Genesis Technology Group, Inc. Partners with Prominent Immunology Researcher to Form Biotechnology Subsidiary: Business Wire - OCT 30, 2001; WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Oct. 30, 2001--Genesis Technology Group, Inc. (OTCBB:GTEC) announced today that it has formed a subsidiary to enter into the biotechnology marketplace. The new company, Biosystems Technologies, Inc. is engaged in the commercialization, marketing and distribution of biomedical pro
U.S. FDA Approves Gilead Sciences' Anti-HIV Drug Viread: Business Wire - October 26, 2001; FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 26, 2001-- Gilead Sciences (Nasdaq:GILD) today announced that it has received U.S. Food and Drug Administration ( FDA ) approval for its antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate) for the treatment of human immunodeficiency virus (HIV) infection when
U.S. FDA Approves Gilead Sciences' Anti-HIV Drug Viread: Business Wire - October 26, 2001; FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 26, 2001-- Gilead Sciences (Nasdaq:GILD) today announced that it has received U.S. Food and Drug Administration ( FDA ) approval for its antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate) for the treatment of human immunodeficiency virus (HIV) infection when
U.S. FDA Approves Gilead Sciences' Anti-HIV Drug Viread: Business Wire - October 26, 2001; FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 26, 2001-- Gilead Sciences (Nasdaq:GILD) today announced that it has received U.S. Food and Drug Administration ( FDA ) approval for its antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate) for the treatment of human
Altachem Pharma Attracts Major Global Partner to Develop Blood Decontamination Technologies: Business Wire - October 24, 2001; EDMONTON, Alberta--(BW HealthWire)--Oct. 24, 2001--Mr. Warren Jackson, President and CEO, is pleased to announce that the company has signed a contract to enter into a joint venture with Erdos Cashmere Group Corporation based in Inner Mongolia , China . The proposed joint venture (JV), subject to all regulatory appr
Altachem Pharma Attracts Major Global Partner to Develop Blood Decontamination Technologies: Business Wire - October 24, 2001; EDMONTON, Alberta--(BW HealthWire)--Oct. 24, 2001--Mr. Warren Jackson, President and CEO, is pleased to announce that the company has signed a contract to enter into a joint venture with Erdos Cashmere Group Corporation based in Inner Mongolia , China . The proposed joint venture (JV), subject to all regulatory appr
Altachem Pharma Attracts Major Global Partner to Develop Blood Decontamination Technologies: Business Wire - October 24, 2001; EDMONTON, Alberta--(BW HealthWire)--Oct. 24, 2001--Mr. Warren Jackson, President and CEO, is pleased to announce that the company has signed a contract to enter into a joint venture with Erdos Cashmere Group Corporation based in Inner Mongolia , China . The proposed joint venture (JV), subject to all regulatory appr
Bastyr University is On the Forefront of HIV Research, But Needs Support From the Affected Community: Bastyr University Study, Funded by the National Institutes of Health, Seeks Subjects to Test Whether Garlic Supplements Can Help Reduce Anti-viral Cocktail Side Effects: Business Wire - October 23, 2001; KENMORE, Wash.--(BUSINESS WIRE)--Oct. 23, 2001-- Garlic is one of the most common herbs used medicinally by HIV positive individuals. But the question remains: does it work and, in particular, is it an answer to unwanted side effects? The anti-viral cocktail of modern AIDS drugs (also called Highly Active Anti-Retrovir
Bastyr University is On the Forefront of HIV Research, But Needs Support From the Affected Community: Bastyr University Study, Funded by the National Institutes of Health, Seeks Subjects to Test Whether Garlic Supplements Can Help Reduce Anti-viral Cocktail Side Effects: Business Wire - October 23, 2001; KENMORE, Wash.--(BUSINESS WIRE)--Oct. 23, 2001-- Garlic is one of the most common herbs used medicinally by HIV positive individuals. But the question remains: does it work and, in particular, is it an answer to unwanted side effects? The anti-viral cocktail of modern AIDS drugs (also called Highly Active Anti-Retrovir
Bastyr University is On the Forefront of HIV Research, But Needs Support From the Affected Community: Bastyr University Study, Funded by the National Institutes of Health, Seeks Subjects to Test Whether Garlic Supplements Can Help Reduce Anti-viral Cocktail Side Effects: Business Wire - October 23, 2001; KENMORE, Wash.--(BUSINESS WIRE)--Oct. 23, 2001-- Garlic is one of the most common herbs used medicinally by HIV positive individuals. But the question remains: does it work and, in particular, is it an answer to unwanted side effects? The anti-viral cocktail of modern AIDS drugs (also called Highly Active Anti-Retrovir
Kaire Selected by Los Angeles County for HIV DAART Study; Agreement To Provide Significant Revenue Growth: Business Wire - October 19, 2001; LOS ANGELES--(BUSINESS WIRE)--Oct. 19, 2001--Kaire Holdings, Inc. s YesRx Health Advocate Program has been selected by the Los Angeles County Department of Health Services, HIV Epidemiology Program, in Collaboration with the Centers for Disease Control and Prevention to be a primary pharmacy provider for their Directly
Kaire Selected by Los Angeles County for HIV DAART Study; Agreement To Provide Significant Revenue Growth: Business Wire - October 19, 2001; LOS ANGELES--(BUSINESS WIRE)--Oct. 19, 2001--Kaire Holdings, Inc. s YesRx Health Advocate Program has been selected by the Los Angeles County Department of Health Services, HIV Epidemiology Program, in Collaboration with the Centers for Disease Control and Prevention to be a primary pharmacy provider for their Directly
Kaire Selected by Los Angeles County for HIV DAART Study; Agreement To Provide Significant Revenue Growth: Business Wire - October 19, 2001; LOS ANGELES--(BUSINESS WIRE)--Oct. 19, 2001--Kaire Holdings, Inc. s YesRx Health Advocate Program has been selected by the Los Angeles County Department of Health Services, HIV Epidemiology Program, in Collaboration with the Centers for Disease Control and Prevention to be a primary pharmacy provider for their Directly
WDI Expands Range of Testing Products in India; Receives Approval for Distribution of TB, Malaria, HCV and HBsAg Tests: Business Wire - October 18, 2001; MIAMI LAKES, Fla.--(BUSINESS WIRE)--Oct. 18, 2001--World Diagnostics, Inc., www.worlddiagnostics.com, a rapidly emerging global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that it received additional approvals and authorization from the Dru
WDI Expands Range of Testing Products in India; Receives Approval for Distribution of TB, Malaria, HCV and HBsAg Tests: Business Wire - October 18, 2001; MIAMI LAKES, Fla.--(BUSINESS WIRE)--Oct. 18, 2001--World Diagnostics, Inc., www.worlddiagnostics.com, a rapidly emerging global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that it received additional approvals and authorization from the Dru
WDI Expands Range of Testing Products in India; Receives Approval for Distribution of TB, Malaria, HCV and HBsAg Tests: Business Wire - October 18, 2001; MIAMI LAKES, Fla.--(BUSINESS WIRE)--Oct. 18, 2001--World Diagnostics, Inc., www.worlddiagnostics.com, a rapidly emerging global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that it received additional approvals and authorization from the Dru
Conant Foundation Receives First Annual Glenn Kawasaki Humanitarian Award: Business Wire - October 10, 2001; SEATTLE--(BW HealthWire)--Oct. 10, 2001--International Therapeutics, Inc. (ITI) announces the establishment of the annual Glenn Kawasaki Humanitarian Award . The award will recognize the efforts of individuals or institutions for accomplishments in the social, scientific, or medical arenas of human disease management.
Conant Foundation Receives First Annual Glenn Kawasaki Humanitarian Award: Business Wire - October 10, 2001; SEATTLE--(BW HealthWire)--Oct. 10, 2001--International Therapeutics, Inc. (ITI) announces the establishment of the annual Glenn Kawasaki Humanitarian Award . The award will recognize the efforts of individuals or institutions for accomplishments in the social, scientific, or medical arenas of human disease management.
Conant Foundation Receives First Annual Glenn Kawasaki Humanitarian Award: Business Wire - October 10, 2001; SEATTLE--(BW HealthWire)--Oct. 10, 2001--International Therapeutics, Inc. (ITI) announces the establishment of the annual Glenn Kawasaki Humanitarian Award . The award will recognize the efforts of individuals or institutions for accomplishments in the social, scientific, or medical arenas of human disease management.
CEL-SCI Corporation Announces Multikine Demonstrates Excellent Clinical Responses in HIV-Infected Women With Human Papilloma Virus -HPV- Induced Cervical Dysplasia: Business Wire - October 9, 2001; VIENNA, Va.--(BUSINESS WIRE)--Oct. 9, 2001--CEL-SCI CORPORATION Elimination of HPV-induced cervical dysplasia demonstrated in majority of treated patients. Presentation at the Annual Meeting of the International Society for Interferon and Cytokine Research in Cleveland, Ohio by scientists from the Institute of Human Vi
CEL-SCI Corporation Announces Multikine Demonstrates Excellent Clinical Responses in HIV-Infected Women With Human Papilloma Virus -HPV- Induced Cervical Dysplasia: Business Wire - October 9, 2001; VIENNA, Va.--(BUSINESS WIRE)--Oct. 9, 2001--CEL-SCI CORPORATION Elimination of HPV-induced cervical dysplasia demonstrated in majority of treated patients. Presentation at the Annual Meeting of the International Society for Interferon and Cytokine Research in Cleveland, Ohio by scientists from the Institute of Human Vi
CEL-SCI Corporation Announces Multikine Demonstrates Excellent Clinical Responses in HIV-Infected Women With Human Papilloma Virus -HPV- Induced Cervical Dysplasia: Business Wire - October 9, 2001; VIENNA, Va.--(BUSINESS WIRE)--Oct. 9, 2001--CEL-SCI CORPORATION Elimination of HPV-induced cervical dysplasia demonstrated in majority of treated patients. Presentation at the Annual Meeting of the International Society for Interferon and Cytokine Research in Cleveland, Ohio by scientists from the Institute of Human Vi
Viral Genetics Inc. and 5 Starliving Online Inc. Announce Closing of Acquisition: Business Wire - October 3, 2001; SEATTLE--(BW HealthWire)--Oct. 3, 2001--5 Starliving Online Inc. and Viral Genetics Inc. are pleased to announce today that they have closed the acquisition disclosed in the press release dated September 18, 2001. Viral Genetics, Inc., a development-stage California corporation, was founded in 1995 to discover, develop
Viral Genetics Inc. and 5 Starliving Online Inc. Announce Closing of Acquisition: Business Wire - October 3, 2001; SEATTLE--(BW HealthWire)--Oct. 3, 2001--5 Starliving Online Inc. and Viral Genetics Inc. are pleased to announce today that they have closed the acquisition disclosed in the press release dated September 18, 2001. Viral Genetics, Inc., a development-stage California corporation, was founded in 1995 to discover, develop
Viral Genetics Inc. and 5 Starliving Online Inc. Announce Closing of Acquisition: Business Wire - October 3, 2001; SEATTLE--(BW HealthWire)--Oct. 3, 2001--5 Starliving Online Inc. and Viral Genetics Inc. are pleased to announce today that they have closed the acquisition disclosed in the press release dated September 18, 2001. Viral Genetics, Inc., a development-stage California corporation, was founded in 1995 to discover, develop
Esoterix Introduces HIVComplete: Business Wire - October 1, 2001; SAN ANTONIO--(BW HealthWire)--Oct. 1, 2001--Esoterix Infectious Disease Center announced the launch of HIVComplete(tm), a new weapon in the fight against AIDS. HIVComplete is the first comprehensive testing and information service focused on the management of HIV, a disease infecting nearly one million Americans. HI
Esoterix Introduces HIVComplete: Business Wire - October 1, 2001; SAN ANTONIO--(BW HealthWire)--Oct. 1, 2001--Esoterix Infectious Disease Center announced the launch of HIVComplete(tm), a new weapon in the fight against AIDS. HIVComplete is the first comprehensive testing and information service focused on the management of HIV, a disease infecting nearly one million Americans. HI
Esoterix Introduces HIVComplete: Business Wire - October 1, 2001; SAN ANTONIO--(BW HealthWire)--Oct. 1, 2001--Esoterix Infectious Disease Center announced the launch of HIVComplete(tm), a new weapon in the fight against AIDS. HIVComplete is the first comprehensive testing and information service focused on the management of HIV, a disease infecting nearly one million Americans. HI
FDA Approval Allows Bio-Reference Laboratories to Begin Marketing Visible Genetics Gene-Based Testing: Visible Genetics Receives FDA Approval For HIV Drug Resistance Testing: Business Wire - September 28, 2001; ELMWOOD PARK, N.J.--(BW HealthWire)--Sept. 28, 2001-- Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced today that it will begin marketing the Visible Genetics TRUGENE(TM) HIV-1 Genotyping Test. Visible Genetics Inc. (VGI, NASDAQ: VGIN) announced on Wednesday that it has received clearance from the U.S. Food an
FDA Approval Allows Bio-Reference Laboratories to Begin Marketing Visible Genetics Gene-Based Testing: Visible Genetics Receives FDA Approval For HIV Drug Resistance Testing: Business Wire - September 28, 2001; ELMWOOD PARK, N.J.--(BW HealthWire)--Sept. 28, 2001-- Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced today that it will begin marketing the Visible Genetics TRUGENE(TM) HIV-1 Genotyping Test. Visible Genetics Inc. (VGI, NASDAQ: VGIN) announced on Wednesday that it has received clearance from the U.S. Food an
FDA Approval Allows Bio-Reference Laboratories to Begin Marketing Visible Genetics Gene-Based Testing: Visible Genetics Receives FDA Approval For HIV Drug Resistance Testing: Business Wire - September 28, 2001; ELMWOOD PARK, N.J.--(BW HealthWire)--Sept. 28, 2001-- Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced today that it will begin marketing the Visible Genetics TRUGENE(TM) HIV-1 Genotyping Test. Visible Genetics Inc. (VGI, NASDAQ: VGIN) announced on Wednesday that it has received clearance from the U.S. Food an
Altachem Pharma Acquires 100% of World Rights to Bionex, a Revolutionary Blood Decontamination Technology: Business Wire - September 26,2001; EDMONTON, Alberta--(BW HealthWire)--Sept. 26, 2001--Warren Jackson, President and Chief Executive Officer of Edmonton-based Altachem Pharma Limited, today announced the successful completion of the formal acquisition of 100% of the world rights to develop, manufacture and sell Bionex(TM), a revolutionary compound desig
Altachem Pharma Acquires 100% of World Rights to Bionex, a Revolutionary Blood Decontamination Technology: Business Wire - September 26,2001; EDMONTON, Alberta--(BW HealthWire)--Sept. 26, 2001--Warren Jackson, President and Chief Executive Officer of Edmonton-based Altachem Pharma Limited, today announced the successful completion of the formal acquisition of 100% of the world rights to develop, manufacture and sell Bionex(TM), a revolutionary compound desig
Altachem Pharma Acquires 100% of World Rights to Bionex, a Revolutionary Blood Decontamination Technology: Business Wire - September 26,2001; EDMONTON, Alberta--(BW HealthWire)--Sept. 26, 2001--Warren Jackson, President and Chief Executive Officer of Edmonton-based Altachem Pharma Limited, today announced the successful completion of the formal acquisition of 100% of the world rights to develop, manufacture and sell Bionex(TM), a revolutionary compound desig
Gilead's Investigational Antiretroviral Agent Viread Reduces Viral Load In HIV Patients With Resistant Virus in Pivotal Phase III Study: Key Data Scheduled for Presentation At Now Postponed ICAAC: Business Wire - September 25, 2001; FOSTER CITY, Calif.--(BUSINESS WIRE)--Sept. 25, 2001-- Gilead Sciences (Nasdaq:GILD) today released 24-week efficacy and safety results from a pivotal Phase III study of its investigational one tablet, once daily antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate). The data were to have been presented at t
Gilead's Investigational Antiretroviral Agent Viread Reduces Viral Load In HIV Patients With Resistant Virus in Pivotal Phase III Study: Key Data Scheduled for Presentation At Now Postponed ICAAC: Business Wire - September 25, 2001; FOSTER CITY, Calif.--(BUSINESS WIRE)--Sept. 25, 2001-- Gilead Sciences (Nasdaq:GILD) today released 24-week efficacy and safety results from a pivotal Phase III study of its investigational one tablet, once daily antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate). The data were to have been presented at t
Gilead's Investigational Antiretroviral Agent Viread Reduces Viral Load In HIV Patients With Resistant Virus in Pivotal Phase III Study: Key Data Scheduled for Presentation At Now Postponed ICAAC: Business Wire - September 25, 2001; FOSTER CITY, Calif.--(BUSINESS WIRE)--Sept. 25, 2001-- Gilead Sciences (Nasdaq:GILD) today released 24-week efficacy and safety results from a pivotal Phase III study of its investigational one tablet, once daily antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate).
Study Suggests Utility of Beckman Coulter iTAg MHC Tetramer Technology for Predicting Development of CMV Disease in Stem Cell Transplant Patients: Business Wire - September 25, 2001; FULLERTON, Calif.--(BW HealthWire)--Sept. 25, 2001--A recent study using iTAg(TM) MHC Tetramers from Beckman Coulter, Inc. (NYSE:BEC) found a correlation between the presence of cytomegalovirus ( CMV )-specific T cells and protection from CMV disease in hematopoietic stem cell transplant patients.
Study Suggests Utility of Beckman Coulter iTAg MHC Tetramer Technology for Predicting Development of CMV Disease in Stem Cell Transplant Patients: Business Wire - September 25, 2001; FULLERTON, Calif.--(BW HealthWire)--Sept. 25, 2001--A recent study using iTAg(TM) MHC Tetramers from Beckman Coulter, Inc. (NYSE:BEC) found a correlation between the presence of cytomegalovirus ( CMV )-specific T cells and protection from CMV disease in hematopoietic stem cell transplant patients. The results of this s
Study Suggests Utility of Beckman Coulter iTAg MHC Tetramer Technology for Predicting Development of CMV Disease in Stem Cell Transplant Patients: Business Wire - September 25, 2001; FULLERTON, Calif.--(BW HealthWire)--Sept. 25, 2001--A recent study using iTAg(TM) MHC Tetramers from Beckman Coulter, Inc. (NYSE:BEC) found a correlation between the presence of cytomegalovirus ( CMV )-specific T cells and protection from CMV disease in hematopoietic stem cell transplant patients. The results of this s
Alpha Therapeutic Obtains First FDA License to Use Polymerase Chain Reaction Testing to Screen Plasma Donations for HIV and Hepatitis C: Business Wire - Septmber 21, 2001; LOS ANGELES--In a landmark advancement for the safety of the nation s supply of plasma derived products, Alpha Therapeutic Corporation today announced it has obtained the first U.S. Food and Drug Administration approval for use of a highly sensitive new testing method for screening plasma donations. The method was deve
Alpha Therapeutic Obtains First FDA License to Use Polymerase Chain Reaction Testing to Screen Plasma Donations for HIV and Hepatitis C: Business Wire - Septmber 21, 2001; LOS ANGELES--In a landmark advancement for the safety of the nation s supply of plasma derived products, Alpha Therapeutic Corporation today announced it has obtained the first U.S. Food and Drug Administration approval for use of a highly sensitive new testing method for screening plasma donations. The method was deve
Alpha Therapeutic Obtains First FDA License to Use Polymerase Chain Reaction Testing to Screen Plasma Donations for HIV and Hepatitis C: Business Wire - Septmber 21, 2001; LOS ANGELES--In a landmark advancement for the safety of the nation s supply of plasma derived products, Alpha Therapeutic Corporation today announced it has obtained the first U.S. Food and Drug Administration approval for use of a highly sensitive new testing method for screening plasma donations. The method was deve
Calypte Announces 'Grassroots' Efforts For HIV-1 Urine Testing; New and Improved Sentinel Testing Service Launched: Business Wire - September 18, 2001; ALAMEDA, Calif.--(BW HealthWire)--Sept. 18, 2001--Calypte Biomedical Corporation announced today progress in their effort to support Community Based Organizations (CBO s), AIDS Service Organizations (ASO s) and Clinics with their painless urine testing alternative. The company has just re-launched its Sentinel(TM) test
Calypte Announces 'Grassroots' Efforts For HIV-1 Urine Testing; New and Improved Sentinel Testing Service Launched: Business Wire - September 18, 2001; ALAMEDA, Calif.--(BW HealthWire)--Sept. 18, 2001--Calypte Biomedical Corporation announced today progress in their effort to support Community Based Organizations (CBO s), AIDS Service Organizations (ASO s) and Clinics with their painless urine testing alternative. The company has just re-launched its Sentinel(TM) test
Calypte Announces 'Grassroots' Efforts For HIV-1 Urine Testing; New and Improved Sentinel Testing Service Launched: Business Wire - September 18, 2001; ALAMEDA, Calif.--(BW HealthWire)--Sept. 18, 2001--Calypte Biomedical Corporation announced today progress in their effort to support Community Based Organizations (CBO s), AIDS Service Organizations (ASO s) and Clinics with their painless urine testing alternative. The company has just re-launched its Sentinel(TM) test
Crompton Donates Compound to the Aaron Diamond AIDS Research Center for Development as Potential Anti-HIV Therapeutic: Leading AIDS Research Center Will Explore Potential Benefits of Crompton Compound: Business Wire - September 17, 2001; GREENWICH, Conn. & NEW YORK--(BUSINESS WIRE)--Sept. 17, 2001-- Crompton Corporation (NYSE:CK) and The Aaron Diamond AIDS Research Center (ADARC) today announced that Crompton has donated certain intellectual property rights for its UC 781 compound to ADARC for development as a possible anti-HIV therapeutic. UC 781
Crompton Donates Compound to the Aaron Diamond AIDS Research Center for Development as Potential Anti-HIV Therapeutic: Leading AIDS Research Center Will Explore Potential Benefits of Crompton Compound: Business Wire - September 17, 2001; GREENWICH, Conn. & NEW YORK--(BUSINESS WIRE)--Sept. 17, 2001-- Crompton Corporation (NYSE:CK) and The Aaron Diamond AIDS Research Center (ADARC) today announced that Crompton has donated certain intellectual property rights for its UC 781 compound to ADARC for development as a possible anti-HIV therapeutic. UC 781
Crompton Donates Compound to the Aaron Diamond AIDS Research Center for Development as Potential Anti-HIV Therapeutic: Leading AIDS Research Center Will Explore Potential Benefits of Crompton Compound: Business Wire - September 17, 2001; GREENWICH, Conn. & NEW YORK--(BUSINESS WIRE)--Sept. 17, 2001-- Crompton Corporation (NYSE:CK) and The Aaron Diamond AIDS Research Center (ADARC) today announced that Crompton has donated certain intellectual property rights for its UC 781 compound to ADARC for development as a possible anti-HIV therapeutic. UC 781
Run for Children's AIDS Still Set for Sunday, September 16: Business Wire - September 14, 2001; SAN FRANCISCO--(BUSINESS WIRE)--Sept. 14, 2001--Bay Area families are invited to watch some of the world s fastest men and women runners and join in races for children and adults during the Champions Run for Children 2001. The third annual event, 8:30 a.m. to 1:00 p.m. on Sunday, September 16 at Kezar Stadium in San Fr
Run for Children's AIDS Still Set for Sunday, September 16: Business Wire - September 14, 2001; SAN FRANCISCO--(BUSINESS WIRE)--Sept. 14, 2001--Bay Area families are invited to watch some of the world s fastest men and women runners and join in races for children and adults during the Champions Run for Children 2001. The third annual event, 8:30 a.m. to 1:00 p.m. on Sunday, September 16 at Kezar Stadium in San Fr
Run for Children's AIDS Still Set for Sunday, September 16: Business Wire - September 14, 2001; SAN FRANCISCO--(BUSINESS WIRE)--Sept. 14, 2001--Bay Area families are invited to watch some of the world s fastest men and women runners and join in races for children and adults during the Champions Run for Children 2001. The third annual event, 8:30 a.m. to 1:00 p.m. on Sunday, September 16 at Kezar Stadium in San Fr
Aethlon Medical Reports 85-100 Percent Removal of HIV from Human Blood and Expands HIV-AIDS Treatment Pipeline: Business Wire - September 10, 2001; LA JOLLA, Calif.--(BW HealthWire)--Sept. 10, 2001--Aethlon Medical announced today that pre-clinical human blood trials of the company s HIV-Hemopurifier(TM) have consistently documented a 55 percent removal of HIV from whole human blood in three hours and an 85-100 percent removal of HIV during the equivalent of one o
Aethlon Medical Reports 85-100 Percent Removal of HIV from Human Blood and Expands HIV-AIDS Treatment Pipeline: Business Wire - September 10, 2001; LA JOLLA, Calif.--(BW HealthWire)--Sept. 10, 2001--Aethlon Medical announced today that pre-clinical human blood trials of the company s HIV-Hemopurifier(TM) have consistently documented a 55 percent removal of HIV from whole human blood in three hours and an 85-100 percent removal of HIV during the equivalent of one o
Aethlon Medical Reports 85-100 Percent Removal of HIV from Human Blood and Expands HIV-AIDS Treatment Pipeline: Business Wire - September 10, 2001; LA JOLLA, Calif.--(BW HealthWire)--Sept. 10, 2001--Aethlon Medical announced today that pre-clinical human blood trials of the company s HIV-Hemopurifier(TM) have consistently documented a 55 percent removal of HIV from whole human blood in three hours and an 85-100 percent removal of HIV during the equivalent of one o
Non-Nucleoside Reverse Transcriptase Inhibitor Is Part of Top HIV Drug Regimen: Business Wire - September 7, 2001; NEWTOWN, Pa.--(BW HealthWire) In the second quarter of 2001, the most often used combination therapy for HIV was Combivir/ Sustiva , which was administered to 12% of patients, according to the HIV Therapy Audit by Scott-Levin, a Quintiles Transnational company (Nasdaq:QTRN).
Non-Nucleoside Reverse Transcriptase Inhibitor Is Part of Top HIV Drug Regimen: Business Wire - September 7, 2001; NEWTOWN, Pa.--(BW HealthWire) In the second quarter of 2001, the most often used combination therapy for HIV was Combivir/ Sustiva , which was administered to 12% of patients, according to the HIV Therapy Audit by Scott-Levin, a Quintiles Transnational company (Nasdaq:QTRN).
Non-Nucleoside Reverse Transcriptase Inhibitor Is Part of Top HIV Drug Regimen: Business Wire - September 7, 2001; NEWTOWN, Pa.--(BW HealthWire) In the second quarter of 2001, the most often used combination therapy for HIV was Combivir / Sustiva , which was administered to 12% of patients, according to the HIV Therapy Audit by
Iguazu Biosciences to Develop a Novel Generation of HIV Vaccines Under License From UCSF: Business Wire - September 6, 2001; SAN FRANCISCO & PHILADELPHIA--(BW HealthWire)--Sept. 6, 2001--Iguazu Biosciences Corp. announced during the AIDS Vaccine 2001 Conference that it was formed to pursue research, manufacturing and clinical development of a novel generation of HIV vaccines. The company is the exclusive worldwide licensee of a patent ap
Iguazu Biosciences to Develop a Novel Generation of HIV Vaccines Under License From UCSF: Business Wire - September 6, 2001; SAN FRANCISCO & PHILADELPHIA--(BW HealthWire)--Sept. 6, 2001--Iguazu Biosciences Corp. announced during the AIDS Vaccine 2001 Conference that it was formed to pursue research, manufacturing and clinical development of a novel generation of HIV vaccines. The company is the exclusive worldwide licensee of a patent ap
Iguazu Biosciences to Develop a Novel Generation of HIV Vaccines Under License From UCSF: Business Wire - September 6, 2001; SAN FRANCISCO & PHILADELPHIA--(BW HealthWire)--Sept. 6, 2001--Iguazu Biosciences Corp. announced during the AIDS Vaccine 2001 Conference that it was formed to pursue research, manufacturing and clinical development of a novel generation of HIV vaccines. The company is the exclusive worldwide licensee of a patent ap
Joint Venture Agreement to Produce Rapid Test Kits for HIV and Tuberculosis in Cape Town South Africa Endorsed by Western Cape Provincial Government: Business Wire - September 5, 2001; EDMONTON, Alberta & CAPE TOWN, South Africa--(BW Healthwire)--Sept. 5, 2001--Medical Services International Inc. (PINK SHEETS:MSITF) is pleased to announce that it has entered into a joint venture agreement with HIVE Manufacturing and Export (SA) of Cape Town, South Africa. As part of the joint venture HIVE Manufac
Joint Venture Agreement to Produce Rapid Test Kits for HIV and Tuberculosis in Cape Town South Africa Endorsed by Western Cape Provincial Government: Business Wire - September 5, 2001; EDMONTON, Alberta & CAPE TOWN, South Africa--(BW Healthwire)--Sept. 5, 2001--Medical Services International Inc. (PINK SHEETS:MSITF) is pleased to announce that it has entered into a joint venture agreement with HIVE Manufacturing and Export (SA) of Cape Town, South Africa. As part of the joint venture HIVE Manufac
Joint Venture Agreement to Produce Rapid Test Kits for HIV and Tuberculosis in Cape Town South Africa Endorsed by Western Cape Provincial Government: Business Wire - September 5, 2001; EDMONTON, Alberta & CAPE TOWN, South Africa--(BW Healthwire)--Sept. 5, 2001--Medical Services International Inc. (PINK SHEETS:MSITF) is pleased to announce that it has entered into a joint venture agreement with HIVE Manufacturing and Export (SA) of Cape Town, South Africa. As part of the joint venture HIVE Manufac
Nutrition 21'S Selenomax Supplement to be Used in a Major NIH-funded Selenium Study: Researchers Look Forward to Confirming Cardiovascular and Immune System Benefits Seen in Earlier Studies: Business Wire - September 5, 2001; Nutrition 21, Inc. (Nasdaq: NXXI) announced today that the Company s Selenomax(R) High Selenium Yeast is being used as the sole source of selenium in an NIH-funded study of selenium intervention in HIV-infected persons. The study, which has already begun patient enrollment, will be conducted at the University of Miami
Nutrition 21'S Selenomax Supplement to be Used in a Major NIH-funded Selenium Study: Researchers Look Forward to Confirming Cardiovascular and Immune System Benefits Seen in Earlier Studies: Business Wire - September 5, 2001; Nutrition 21, Inc. (Nasdaq: NXXI) announced today that the Company s Selenomax(R) High Selenium Yeast is being used as the sole source of selenium in an NIH-funded study of selenium intervention in HIV-infected persons. The study, which has already begun patient enrollment, will be conducted at the University of Miami
Nutrition 21'S Selenomax Supplement to be Used in a Major NIH-funded Selenium Study: Researchers Look Forward to Confirming Cardiovascular and Immune System Benefits Seen in Earlier Studies: Business Wire - September 5, 2001; Nutrition 21, Inc. (Nasdaq: NXXI) announced today that the Company s Selenomax(R) High Selenium Yeast is being used as the sole source of selenium in an NIH-funded study of selenium intervention in HIV-infected persons. The study, which has already begun patient enrollment, will be conducted at the University of Miami
Medical Services Completes Initial Order for Rapid HIV and TB Test Kits: Business Wire - August 20, 2001; EDMONTON, Alberta--(BW HealthWire)--Aug. 20, 2001--Medical Services International Inc. (Pink Sheets:MSITF) is pleased to announce that it has signed an agreement to supply an initial order of 50,000 rapid test kits for both HIV and Tuberculosis (TB) to HIVE Exports (SA) (PTY) Ltd. of Cape Town, South Africa
Medical Services Completes Initial Order for Rapid HIV and TB Test Kits: Business Wire - August 20, 2001; EDMONTON, Alberta--(BW HealthWire)--Aug. 20, 2001--Medical Services International Inc. (Pink Sheets:MSITF) is pleased to announce that it has signed an agreement to supply an initial order of 50,000 rapid test kits for both HIV and Tuberculosis (TB) to HIVE Exports (SA) (PTY) Ltd. of Cape Town, South Africa
Medical Services Completes Initial Order for Rapid HIV and TB Test Kits: Business Wire - August 20, 2001; EDMONTON, Alberta--(BW HealthWire)--Aug. 20, 2001--Medical Services International Inc. (Pink Sheets:MSITF) is pleased to announce that it has signed an agreement to supply an initial order of 50,000 rapid test kits for both HIV and Tuberculosis (TB) to HIVE Exports (SA) (PTY) Ltd. of Cape Town, South Africa
American Liver Foundation Announces Collaboration With Veritas Medicine to Increase Hepatitis C Awareness and Clinical Trial Enrollment: Business Wire - August 20,2001; NEW YORK, NY & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 20, 2001-- The American Liver Foundation (ALF), the leading national voluntary health organization dedicated to preventing, treating and curing hepatitis and other liver diseases, and Veritas Medicine, a comprehensive online clinical trials and treatment resour
American Liver Foundation Announces Collaboration With Veritas Medicine to Increase Hepatitis C Awareness and Clinical Trial Enrollment: Business Wire - August 20,2001; NEW YORK, NY & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 20, 2001-- The American Liver Foundation (ALF), the leading national voluntary health organization dedicated to preventing, treating and curing hepatitis and other liver diseases, and Veritas Medicine, a comprehensive online clinical trials and treatment resour
American Liver Foundation Announces Collaboration With Veritas Medicine to Increase Hepatitis C Awareness and Clinical Trial Enrollment: Business Wire - August 20,2001; NEW YORK, NY & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 20, 2001-- The American Liver Foundation (ALF), the leading national voluntary health organization dedicated to preventing, treating and curing hepatitis and other liver diseases, and Veritas Medicine, a comprehensive online clinical trials and treatment resour
Cytran Announces Preliminary Results of Phase III KS Trial: Business Wire - August 17, 2001; KIRKLAND, Wash.--(BW HealthWire)--Aug. 17, 2001--Cytran announced today that preliminary results of a Phase III clinical trial using IM862 as a monotherapy in AIDS-related Kaposi s sarcoma (KS) did not meet primary efficacy objectives. The Phase III trial reconfirmed the excellent safety and side effect profile IM862 d
Cytran Announces Preliminary Results of Phase III KS Trial: Business Wire - August 17, 2001; KIRKLAND, Wash.--(BW HealthWire)--Aug. 17, 2001--Cytran announced today that preliminary results of a Phase III clinical trial using IM862 as a monotherapy in AIDS-related Kaposi s sarcoma (KS) did not meet primary efficacy objectives. The Phase III trial reconfirmed the excellent safety and side effect profile IM862 d
Cytran Announces Preliminary Results of Phase III KS Trial: Business Wire - August 17, 2001; KIRKLAND, Wash.--(BW HealthWire)--Aug. 17, 2001--Cytran announced today that preliminary results of a Phase III clinical trial using IM862 as a monotherapy in AIDS-related Kaposi s sarcoma (KS) did not meet primary efficacy objectives. The Phase III trial reconfirmed the excellent safety and side effect profile IM862 d
Bio-Plexus Begins Commercialization of PUNCTUR-GUARD Safety Winged Set for Blood Collection: Business Wire - August 16, 2001; VERNON, Conn.--(BUSINESS WIRE)--Aug. 16, 2001--Bio-Plexus, Inc., (Pink Sheets: BPXS) a leader in the design, manufacture and marketing of safety medical needles, today announced that it has begun fulfilling customer orders for its PUNCTUR-GUARD(R) Safety Winged Set for Blood Collection. This commercialization follows t
Bio-Plexus Begins Commercialization of PUNCTUR-GUARD Safety Winged Set for Blood Collection: Business Wire - August 16, 2001; VERNON, Conn.--(BUSINESS WIRE)--Aug. 16, 2001--Bio-Plexus, Inc., (Pink Sheets: BPXS) a leader in the design, manufacture and marketing of safety medical needles, today announced that it has begun fulfilling customer orders for its PUNCTUR-GUARD(R) Safety Winged Set for Blood Collection. This commercialization follows t
Bio-Plexus Begins Commercialization of PUNCTUR-GUARD Safety Winged Set for Blood Collection: Business Wire - August 16, 2001; VERNON, Conn.--(BUSINESS WIRE)--Aug. 16, 2001--Bio-Plexus, Inc., (Pink Sheets: BPXS) a leader in the design, manufacture and marketing of safety medical needles, today announced that it has begun fulfilling customer orders for its PUNCTUR-GUARD(R) Safety Winged Set for Blood Collection. This commercialization follows t
Development of T-20 On Track: Roche and Trimeris announced this morning that they have completed enrollment in the Phase III program for T-20: Business Wire - August 9, 2001; NUTLEY, N.J. and DURHAM, N.C. - Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced that both adult pivotal Phase III clinical studies for T-20 are fully enrolled. Approximately 1,000 people living with HIV across Europe, Australia , North America and Brazil are currently participating in studies to eva
Development of T-20 On Track: Roche and Trimeris announced this morning that they have completed enrollment in the Phase III program for T-20: Business Wire - August 9, 2001; NUTLEY, N.J. and DURHAM, N.C. - Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced that both adult pivotal Phase III clinical studies for T-20 are fully enrolled. Approximately 1,000 people living with HIV across Europe, Australia , North America and Brazil are currently participating in studies to eva
Development of T-20 On Track: Roche and Trimeris announced this morning that they have completed enrollment in the Phase III program for T-20: Business Wire - August 9, 2001; NUTLEY, N.J. and DURHAM, N.C. - Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced that both adult pivotal Phase III clinical studies for T-20 are fully enrolled. Approximately 1,000 people living with HIV across Europe, Australia , North America and Brazil are currently participating in studies to eva
Trimeris and Array BioPharma Sign Antiviral Drug Discovery Agreement: Business Wire - August 06,2001; DURHAM, N.C. and BOULDER, Colo.--(BUSINESS WIRE)--Aug. 6, 2001-- Collaboration to target discovery and development of small molecule fusion inhibitors of HIV and RSV Trimeris, Inc. (Nasdaq: TRMS) and Array BioPharma Inc. (Nasdaq: ARRY) today announced the signing of an agreement to discover small molecule fusion inhibi
Trimeris and Array BioPharma Sign Antiviral Drug Discovery Agreement: Business Wire - August 06,2001; DURHAM, N.C. and BOULDER, Colo.--(BUSINESS WIRE)--Aug. 6, 2001-- Collaboration to target discovery and development of small molecule fusion inhibitors of HIV and RSV Trimeris, Inc. (Nasdaq: TRMS) and Array BioPharma Inc. (Nasdaq: ARRY) today announced the signing of an agreement to discover small molecule fusion inhibi
Trimeris and Array BioPharma Sign Antiviral Drug Discovery Agreement: Business Wire - August 06,2001; DURHAM, N.C. and BOULDER, Colo.--(BUSINESS WIRE)--Aug. 6, 2001-- Collaboration to target discovery and development of small molecule fusion inhibitors of HIV and RSV Trimeris, Inc. (Nasdaq: TRMS) and Array BioPharma Inc. (Nasdaq: ARRY) today announced the signing of an agreement to discover small molecule fusion inhibi
Seattle Jaycees' Battle Against Juvenile AIDS in Africa Receives Rare International Recognition: Business Wire - August 03, 2001; SEATTLE--(BUSINESS WIRE)--August 3, 2001-- Kenya Kids AIDS Project, Chapter President Trip Highlight Impact of Local Donations The Seattle Junior Chamber of Commerce (Jaycees) is pleased to announce its initiative to help combat juvenile AIDS in Africa -- Kenya Kids AIDS Project (KKAP) -- will receive international rec
Seattle Jaycees' Battle Against Juvenile AIDS in Africa Receives Rare International Recognition: Business Wire - August 03, 2001; SEATTLE--(BUSINESS WIRE)--August 3, 2001-- Kenya Kids AIDS Project, Chapter President Trip Highlight Impact of Local Donations The Seattle Junior Chamber of Commerce (Jaycees) is pleased to announce its initiative to help combat juvenile AIDS in Africa -- Kenya Kids AIDS Project (KKAP) -- will receive international rec
Seattle Jaycees' Battle Against Juvenile AIDS in Africa Receives Rare International Recognition: Business Wire - August 03, 2001; SEATTLE--(BUSINESS WIRE)--August 3, 2001-- Kenya Kids AIDS Project, Chapter President Trip Highlight Impact of Local Donations The Seattle Junior Chamber of Commerce (Jaycees) is pleased to announce its initiative to help combat juvenile AIDS in Africa -- Kenya Kids AIDS Project (KKAP) -- will receive international rec
CollaGenex Pharmaceuticals Announces Initiation of Phase II Clinical Trial in Kaposi's Sarcoma With Proprietary Angiogenesis Inhibitor: Business Wire - August 02, 2001; NEWTOWN, Pa.--(BW HealthWire)--Aug. 2, 2001-- AIDS Malignancy Consortium Sponsored by the National Cancer Institute Opens a Multi-Center Study to Determine the Response Rate of COL-3 (Metastat(R)) in Patients with HIV-Related Kaposi s Sarcoma CollaGenex Pharmaceuticals (NASDAQ: CGPI) today announced that the AIDS Malig
CollaGenex Pharmaceuticals Announces Initiation of Phase II Clinical Trial in Kaposi's Sarcoma With Proprietary Angiogenesis Inhibitor: Business Wire - August 02, 2001; NEWTOWN, Pa.--(BW HealthWire)--Aug. 2, 2001-- AIDS Malignancy Consortium Sponsored by the National Cancer Institute Opens a Multi-Center Study to Determine the Response Rate of COL-3 (Metastat(R)) in Patients with HIV-Related Kaposi s Sarcoma CollaGenex Pharmaceuticals (NASDAQ: CGPI) today announced that the AIDS Malig
CollaGenex Pharmaceuticals Announces Initiation of Phase II Clinical Trial in Kaposi's Sarcoma With Proprietary Angiogenesis Inhibitor: Business Wire - August 02, 2001; NEWTOWN, Pa.--(BW HealthWire)--Aug. 2, 2001-- AIDS Malignancy Consortium Sponsored by the National Cancer Institute Opens a Multi-Center Study to Determine the Response Rate of COL-3 (Metastat(R)) in Patients with HIV-Related Kaposi s Sarcoma CollaGenex Pharmaceuticals (NASDAQ: CGPI) today announced that the AIDS Malig
Applied Biosystems: ViroSeq HIV-1 Genotyping System 510k Premarket Notification Submitted to FDA: Business Wire - July 31,2001; ALAMEDA, Calif.--(BW HealthWire)--July 31, 2001--Celera Diagnostics, a joint venture of Applied Biosystems Group (NYSE:ABI) and Celera Genomics Group (NYSE:CRA), Applera Corporation businesses, announced that a 510(k) Premarket Notification has been submitted to the U.S. Food and Drug Administration, seeking marketing
Applied Biosystems: ViroSeq HIV-1 Genotyping System 510k Premarket Notification Submitted to FDA: Business Wire - July 31,2001; ALAMEDA, Calif.--(BW HealthWire)--July 31, 2001--Celera Diagnostics, a joint venture of Applied Biosystems Group (NYSE:ABI) and Celera Genomics Group (NYSE:CRA), Applera Corporation businesses, announced that a 510(k) Premarket Notification has been submitted to the U.S. Food and Drug Administration, seeking marketing
Applied Biosystems: ViroSeq HIV-1 Genotyping System 510k Premarket Notification Submitted to FDA: Business Wire - July 31,2001; ALAMEDA, Calif.--(BW HealthWire)--July 31, 2001--Celera Diagnostics, a joint venture of Applied Biosystems Group (NYSE:ABI) and Celera Genomics Group (NYSE:CRA), Applera Corporation businesses, announced that a 510(k) Premarket Notification has been submitted to the U.S. Food and Drug Administration, seeking marketing
Biokeys Pharmaceuticals Inc. Announces Additional HIV/AIDS Cell Mediated Immunity Vaccine Patent: Business Wire - July 25,2001; SAN DIEGO--(BW HealthWire)--June 25, 2001--Biokeys Pharmaceuticals Inc. (Pink Sheets:BKYS) announced today that United States Patent number 6,265,539 entitled Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome has been issued to the Board of Regents of The University of Texas. The inventor is Dr. Ralph Arlin
Biokeys Pharmaceuticals Inc. Announces Additional HIV/AIDS Cell Mediated Immunity Vaccine Patent: Business Wire - July 25,2001; SAN DIEGO--(BW HealthWire)--June 25, 2001--Biokeys Pharmaceuticals Inc. (Pink Sheets:BKYS) announced today that United States Patent number 6,265,539 entitled Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome has been issued to the Board of Regents of The University of Texas. The inventor is Dr. Ralph Arlin
Biokeys Pharmaceuticals Inc. Announces Additional HIV/AIDS Cell Mediated Immunity Vaccine Patent: Business Wire - July 25,2001; SAN DIEGO--(BW HealthWire)--June 25, 2001--Biokeys Pharmaceuticals Inc. (Pink Sheets:BKYS) announced today that United States Patent number 6,265,539 entitled Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome has been issued to the Board of Regents of The University of Texas. The inventor is Dr. Ralph Arlin
CALCOL To Make and Sell ZER Quick AIDS Test Kits: CALCOL INC. & ZER HITECH LTD. To Make, Sell and Distribute Quick AIDS Test Kits At Low Cost for High Impact AIDS Areas: Offers Test Kits to Major Relief Agencies: Mass Screening Could Lead to Disease Prevention, Treatment, and Control: Business Wire - July 23, 2001; CALCOL INC. (OTC:CLCL) a development stage U.S. holding company for China manufacturing companies in pharmaceuticals (Calcol Changbaishan Pharmaceutical Ltd. Shenzhen, China) and soft drinks (Sanhe Meile Soft Drinks Ltd. Beijing, China), announced today that it has signed a binding letter of intent effective July 19, 2
CALCOL To Make and Sell ZER Quick AIDS Test Kits: CALCOL INC. & ZER HITECH LTD. To Make, Sell and Distribute Quick AIDS Test Kits At Low Cost for High Impact AIDS Areas: Offers Test Kits to Major Relief Agencies: Mass Screening Could Lead to Disease Prevention, Treatment, and Control: Business Wire - July 23, 2001; CALCOL INC. (OTC:CLCL) a development stage U.S. holding company for China manufacturing companies in pharmaceuticals (Calcol Changbaishan Pharmaceutical Ltd. Shenzhen, China) and soft drinks (Sanhe Meile Soft Drinks Ltd. Beijing, China), announced today that it has signed a binding letter of intent effective July 19, 2
CALCOL To Make and Sell ZER Quick AIDS Test Kits: CALCOL INC. & ZER HITECH LTD. To Make, Sell and Distribute Quick AIDS Test Kits At Low Cost for High Impact AIDS Areas: Offers Test Kits to Major Relief Agencies: Mass Screening Could Lead to Disease Prevention, Treatment, and Control: Business Wire - July 23, 2001; CALCOL INC. (OTC:CLCL) a development stage U.S. holding company for China manufacturing companies in pharmaceuticals (Calcol Changbaishan Pharmaceutical Ltd. Shenzhen, China) and soft drinks (Sanhe Meile Soft Drinks Ltd. Beijing, China), announced today that it has signed a binding letter of intent effective July 19, 2
Gender-Specific Differences in Biology of Heterosexual HIV-1 Transmission Are Suggested by African Study Reported in AIDS Research and Human Retroviruses: Business Wire - July 18, 2001; LARCHMONT, N.Y.--In a study of more than a thousand heterosexual couples in sub-Saharan Africa, where over 80% of the world s HIV-infected adults live, a team of researchers from the University of Alabama at Birmingham (UAB) working with scientists in Zambia found that the risk of transmission of HIV-1 between the sexe
Gender-Specific Differences in Biology of Heterosexual HIV-1 Transmission Are Suggested by African Study Reported in AIDS Research and Human Retroviruses: Business Wire - July 18, 2001; LARCHMONT, N.Y.--In a study of more than a thousand heterosexual couples in sub-Saharan Africa, where over 80% of the world s HIV-infected adults live, a team of researchers from the University of Alabama at Birmingham (UAB) working with scientists in Zambia found that the risk of transmission of HIV-1 between the sexe
Gender-Specific Differences in Biology of Heterosexual HIV-1 Transmission Are Suggested by African Study Reported in AIDS Research and Human Retroviruses: Business Wire - July 18, 2001; LARCHMONT, N.Y.--In a study of more than a thousand heterosexual couples in sub-Saharan Africa, where over 80% of the world s HIV-infected adults live, a team of researchers from the University of Alabama at Birmingham (UAB) working with scientists in Zambia found that the risk of transmission of HIV-1 between the sexe
Esoterix Introduces HIVComplete: Business Wire - July 18, 2001; SAN ANTONIO--(BW HealthWire)--July 18, 2001--Esoterix Infectious Disease Center announced the launch of HIVComplete(tm), a new weapon in the fight against AIDS. HIVComplete is the first comprehensive testing and information service focused on the management of HIV, a disease infecting nearly one million Americans.
Esoterix Introduces HIVComplete: Business Wire - July 18, 2001; SAN ANTONIO--(BW HealthWire)--July 18, 2001--Esoterix Infectious Disease Center announced the launch of HIVComplete(tm), a new weapon in the fight against AIDS. HIVComplete is the first comprehensive testing and information service focused on the management of HIV, a disease infecting nearly one million Americans.
Esoterix Introduces HIVComplete: Business Wire - July 18, 2001; SAN ANTONIO--(BW HealthWire)--July 18, 2001--Esoterix Infectious Disease Center announced the launch of HIVComplete(tm), a new weapon in the fight against AIDS. HIVComplete is the first comprehensive testing and information service focused on the management of HIV, a disease infecting nearly one million Americans.
Product R, The Immunomodulator from Advanced Viral Research Corp., Enhances Secretion of Proinflammatory Chemokines IL-8 and MCP-1 in Human Monocytes: Business Wire - July 17, 2001; YONKERS, N.Y.--July 17, 2001--Advanced Viral Research Corp. (OTCBB: ADVR) today announced the publication of a scientific research paper showing that Product R, the Company s peptide-nucleic acid immunomodulator, enhances the production of two proteins that boost the immune response during viral infection. The paper, e
Product R, The Immunomodulator from Advanced Viral Research Corp., Enhances Secretion of Proinflammatory Chemokines IL-8 and MCP-1 in Human Monocytes: Business Wire - July 17, 2001; YONKERS, N.Y.--July 17, 2001--Advanced Viral Research Corp. (OTCBB: ADVR) today announced the publication of a scientific research paper showing that Product R, the Company s peptide-nucleic acid immunomodulator, enhances the production of two proteins that boost the immune response during viral infection. The paper, e
Product R, The Immunomodulator from Advanced Viral Research Corp., Enhances Secretion of Proinflammatory Chemokines IL-8 and MCP-1 in Human Monocytes: Business Wire - July 17, 2001; YONKERS, N.Y.--July 17, 2001--Advanced Viral Research Corp. (OTCBB: ADVR) today announced the publication of a scientific research paper showing that Product R, the Company s peptide-nucleic acid immunomodulator, enhances the production of two proteins that boost the immune response during viral infection. The paper, e
Franc-Or Resources: Urrma Officially Opens New Lab and Appoints Professor Jean-Claude Chermann as Full-Time Scientific Director: Business Wire - July 12, 2001; MONTREAL--Franc-Or Resources Corporation (TSE:FOR.) is pleased to announce that URRMA Biopharma Inc., a private Montreal-based biotech company into which the Company recently invested $2 million, has completed construction of a new research laboratory in Aubagne, France , near Marseille. The opening ceremony on Jul
Franc-Or Resources: Urrma Officially Opens New Lab and Appoints Professor Jean-Claude Chermann as Full-Time Scientific Director: Business Wire - July 12, 2001; MONTREAL--Franc-Or Resources Corporation (TSE:FOR.) is pleased to announce that URRMA Biopharma Inc., a private Montreal-based biotech company into which the Company recently invested $2 million, has completed construction of a new research laboratory in Aubagne, France , near Marseille. The opening ceremony on Jul
Franc-Or Resources: Urrma Officially Opens New Lab and Appoints Professor Jean-Claude Chermann as Full-Time Scientific Director: Business Wire - July 12, 2001; MONTREAL--Franc-Or Resources Corporation (TSE:FOR.) is pleased to announce that URRMA Biopharma Inc., a private Montreal-based biotech company into which the Company recently invested $2 million, has completed construction of a new research laboratory in Aubagne, France , near Marseille. The opening ceremony on Jul
Hemispherx Biopharma Announces Strategic Alliance With Empire Health Resources for HIV, Hepatitis C Clinical Research: Business Wire - July 12, 2001; PHILADELPHIA--Hemispherx Biopharma, Inc. (AMEX: HEB), a leading biopharmaceutical company specializing in the development of nucleic acids (NA) to enhance anti-viral defense systems in the human body, announced today a strategic partnership with Empire Health Resources, the nation s leading privately held healthcare ma
Hemispherx Biopharma Announces Strategic Alliance With Empire Health Resources for HIV, Hepatitis C Clinical Research: Business Wire - July 12, 2001; PHILADELPHIA--Hemispherx Biopharma, Inc. (AMEX: HEB), a leading biopharmaceutical company specializing in the development of nucleic acids (NA) to enhance anti-viral defense systems in the human body, announced today a strategic partnership with Empire Health Resources, the nation s leading privately held healthcare ma
Hemispherx Biopharma Announces Strategic Alliance With Empire Health Resources for HIV, Hepatitis C Clinical Research: Business Wire - July 12, 2001; PHILADELPHIA--Hemispherx Biopharma, Inc. (AMEX: HEB), a leading biopharmaceutical company specializing in the development of nucleic acids (NA) to enhance anti-viral defense systems in the human body, announced today a strategic partnership with Empire Health Resources, the nation s leading privately held healthcare ma
OraSure Technologies Files for Pre-Market Approval of OraQuick Rapid HIV Test: Business Wire - July 11, 2001; BETHLEHEM, Pa.--(BW HealthWire)--July 11, 2001--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that has filed with the U.S. Food and Drug Administration ( FDA ) for Pre-Market Approval of its OraQuick(R) HIV test. OraQuick is a rapid test device that can detect antibodies to the HIV disease within 20 minutes,
OraSure Technologies Files for Pre-Market Approval of OraQuick Rapid HIV Test: Business Wire - July 11, 2001; BETHLEHEM, Pa.--(BW HealthWire)--July 11, 2001--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that has filed with the U.S. Food and Drug Administration ( FDA ) for Pre-Market Approval of its OraQuick(R) HIV test. OraQuick is a rapid test device that can detect antibodies to the HIV disease within 20 minutes,
OraSure Technologies Files for Pre-Market Approval of OraQuick Rapid HIV Test: Business Wire - July 11, 2001; BETHLEHEM, Pa.--(BW HealthWire)--July 11, 2001--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that has filed with the U.S. Food and Drug Administration ( FDA ) for Pre-Market Approval of its OraQuick(R) HIV test. OraQuick is a rapid test device that can detect antibodies to the HIV disease within 20 minutes,
Study Examines Impact of Long-Term Administration of T-20 On Daily Life: Eighty-Five Percent of Patients Report Subcutaneous Delivery Does Not Substantially Affect Daily Activities: Business Wire - July 11, 2001; BUENOS AIRES, Argentina--(BW HealthWire)--July 11, 2001--Data evaluating patient acceptance of the subcutaneous administration of T-20, an investigational HIV fusion inhibitor being developed jointly by Roche and Trimeris (Nasdaq: TRMS), are being presented today at the First International AIDS Society (IAS) Conference
Study Examines Impact of Long-Term Administration of T-20 On Daily Life: Eighty-Five Percent of Patients Report Subcutaneous Delivery Does Not Substantially Affect Daily Activities: Business Wire - July 11, 2001; BUENOS AIRES, Argentina--(BW HealthWire)--July 11, 2001--Data evaluating patient acceptance of the subcutaneous administration of T-20, an investigational HIV fusion inhibitor being developed jointly by Roche and Trimeris (Nasdaq: TRMS), are being presented today at the First International AIDS Society (IAS) Conference
Study Examines Impact of Long-Term Administration of T-20 On Daily Life: Eighty-Five Percent of Patients Report Subcutaneous Delivery Does Not Substantially Affect Daily Activities: Business Wire - July 11, 2001; BUENOS AIRES, Argentina--(BW HealthWire)--July 11, 2001--Data evaluating patient acceptance of the subcutaneous administration of T-20, an investigational HIV fusion inhibitor being developed jointly by Roche and Trimeris (Nasdaq: TRMS), are being presented today at the First International AIDS Society (IAS) Conference
Roche and Trimeris Correct Previous Announcement on Complete Enrollment in T-20 Phase III Clinical Trial: Business Wire - June 28, 2001; CORRECTION...by Trimeris NOTE: The following news release replaces and corrects the previous Trimeris news release which ran earlier Thursday on Business Wire, BW2100 (NJ-TRIMERIS/ROCHE) NUTLEY, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--June 28, 2001--Roche and Trimeris, Inc. (NASDAQ: TRMS) today announced the completi
Roche and Trimeris Correct Previous Announcement on Complete Enrollment in T-20 Phase III Clinical Trial: Business Wire - June 28, 2001; CORRECTION...by Trimeris NOTE: The following news release replaces and corrects the previous Trimeris news release which ran earlier Thursday on Business Wire, BW2100 (NJ-TRIMERIS/ROCHE) NUTLEY, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--June 28, 2001--Roche and Trimeris, Inc. (NASDAQ: TRMS) today announced the completi
Roche and Trimeris Correct Previous Announcement on Complete Enrollment in T-20 Phase III Clinical Trial: Business Wire - June 28, 2001; CORRECTION...by Trimeris NOTE: The following news release replaces and corrects the previous Trimeris news release which ran earlier Thursday on Business Wire, BW2100 (NJ-TRIMERIS/ROCHE) NUTLEY, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--June 28, 2001--Roche and Trimeris, Inc. (NASDAQ: TRMS) today announced the completi
FDA Approves Conversion of Calypte Urine Western Blot BLA to Premarket Approval Status: Conversion of Regulatory Status Will Improve Production Efficiency and Reduce Production Costs: Business Wire - June 27, 2001; ALAMEDA, Calif.--(BUSINESS WIRE)--June 27, 2001-- Calypte Biomedical Corporation (Nasdaq: CALY) announced today that the United States Food and Drug Administration ( FDA ) has approved Calypte s premarket approval application (PMA) for the Cambridge Biotech(TM) HIV-1 Urine Western Blot. Calypte envisions a number o
FDA Approves Conversion of Calypte Urine Western Blot BLA to Premarket Approval Status: Conversion of Regulatory Status Will Improve Production Efficiency and Reduce Production Costs: Business Wire - June 27, 2001; ALAMEDA, Calif.--(BUSINESS WIRE)--June 27, 2001-- Calypte Biomedical Corporation (Nasdaq: CALY) announced today that the United States Food and Drug Administration ( FDA ) has approved Calypte s premarket approval application (PMA) for the Cambridge Biotech(TM) HIV-1 Urine Western Blot. Calypte envisions a number o
FDA Approves Conversion of Calypte Urine Western Blot BLA to Premarket Approval Status: Conversion of Regulatory Status Will Improve Production Efficiency and Reduce Production Costs: Business Wire - June 27, 2001; ALAMEDA, Calif.--(BUSINESS WIRE)--June 27, 2001-- Calypte Biomedical Corporation (Nasdaq: CALY) announced today that the United States Food and Drug Administration ( FDA ) has approved Calypte s premarket approval application (PMA) for the Cambridge Biotech(TM) HIV-1 Urine Western Blot. Calypte envisions a number o
Immtech Announces New Direction for Tuberculosis Research Facility: Business Wire - June 21, 2001; VERNON HILLS, Ill.--(BW HealthWire)--June 21, 2001--Immtech International, Inc., (NASDAQ NMS:IMMT), a biopharmaceutical company focused on the discovery and commercialization of drugs for the treatment of fungal diseases, tuberculosis , hepatitis, pneumonia, diarrhea, and cancer, announced today that Dr. Scott Franzbla
Immtech Announces New Direction for Tuberculosis Research Facility: Business Wire - June 21, 2001; VERNON HILLS, Ill.--(BW HealthWire)--June 21, 2001--Immtech International, Inc., (NASDAQ NMS:IMMT), a biopharmaceutical company focused on the discovery and commercialization of drugs for the treatment of fungal diseases, tuberculosis , hepatitis , pneumonia, diarrhea, and cancer, announced today that Dr.
Immtech Announces New Direction for Tuberculosis Research Facility: Business Wire - June 21, 2001; VERNON HILLS, Ill.--(BW HealthWire)--June 21, 2001--Immtech International, Inc., (NASDAQ NMS:IMMT), a biopharmaceutical company focused on the discovery and commercialization of drugs for the treatment of fungal diseases, tuberculosis , hepatitis , pneumonia, diarrhea, and cancer, announced today that Dr.
Roche and Trimeris Broaden Scope of HIV Partnership; Three Year Joint Research Agreement to Identify and Commercialize Additional HIV Fusion Inhibitor Peptides: Business Wire - June 19, 2001; NUTLEY, N.J. & DURHAM, N.C.--(BW HealthWire)--June 19, 2001--Roche and Trimeris, Inc. announced today the signing of a research agreement to discover, develop and commercialize novel generations of HIV fusion inhibitor peptides. This agreement expands upon a 1999 worldwide partnership agreement between the two comp
Roche and Trimeris Broaden Scope of HIV Partnership; Three Year Joint Research Agreement to Identify and Commercialize Additional HIV Fusion Inhibitor Peptides: Business Wire - June 19, 2001; NUTLEY, N.J. & DURHAM, N.C.--(BW HealthWire)--June 19, 2001--Roche and Trimeris, Inc. announced today the signing of a research agreement to discover, develop and commercialize novel generations of HIV fusion inhibitor peptides. This agreement expands upon a 1999 worldwide partnership agreement between the two comp
Roche and Trimeris Broaden Scope of HIV Partnership; Three Year Joint Research Agreement to Identify and Commercialize Additional HIV Fusion Inhibitor Peptides: Business Wire - June 19, 2001; NUTLEY, N.J. & DURHAM, N.C.--(BW HealthWire)--June 19, 2001--Roche and Trimeris, Inc. announced today the signing of a research agreement to discover, develop and commercialize novel generations of HIV fusion inhibitor peptides. This agreement expands upon a 1999 worldwide partnership agreement between the two comp
Center for Special Immunology -CSI- to Begin a New Study Involving Immune-Based Therapy Together With Strategic Therapeutic Interruptions -STI's- for Patients Living With HIV-Infection: Business Wire - June 7, 2001; FOUNTAIN VALLEY, Calif.--(BW HealthWire)--June 7, 2001--The Orange County Center for Special Immunology (CSI) announced today that it will begin a research trial involving a new approach to treating human immunedeficiency virus (HIV) infection. The study will involve using immune-based therapy with the medication Ampli
Center for Special Immunology -CSI- to Begin a New Study Involving Immune-Based Therapy Together With Strategic Therapeutic Interruptions -STI's- for Patients Living With HIV-Infection: Business Wire - June 7, 2001; FOUNTAIN VALLEY, Calif.--(BW HealthWire)--June 7, 2001--The Orange County Center for Special Immunology (CSI) announced today that it will begin a research trial involving a new approach to treating human immunedeficiency virus (HIV) infection. The study will involve using immune-based therapy with the medication Ampli
Center for Special Immunology -CSI- to Begin a New Study Involving Immune-Based Therapy Together With Strategic Therapeutic Interruptions -STI's- for Patients Living With HIV-Infection: Business Wire - June 7, 2001; FOUNTAIN VALLEY, Calif.--(BW HealthWire)--June 7, 2001--The Orange County Center for Special Immunology (CSI) announced today that it will begin a research trial involving a new approach to treating human immunedeficiency virus (HIV) infection. The study will involve using immune-based therapy with the medication Ampli
Epicyte Receives SBIR Grant to Fund HPV Antibody Development; Marks Fifth Grant for Epicyte to Develop Sexual Health Products: Business Wire - June 5, 2001; SAN DIEGO--(BW HealthWire)--June 5, 2001--Epicyte Pharmaceutical Inc. today announced that the Company has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health for the development of antibodies to prevent the transmission of human papillomavirus (
Epicyte Receives SBIR Grant to Fund HPV Antibody Development; Marks Fifth Grant for Epicyte to Develop Sexual Health Products: Business Wire - June 5, 2001; SAN DIEGO--(BW HealthWire)--June 5, 2001--Epicyte Pharmaceutical Inc. today announced that the Company has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health for the development of antibodies to prevent the transmission of human papillomavirus (
Epicyte Receives SBIR Grant to Fund HPV Antibody Development; Marks Fifth Grant for Epicyte to Develop Sexual Health Products: Business Wire - June 5, 2001; SAN DIEGO--(BW HealthWire)--June 5, 2001--Epicyte Pharmaceutical Inc. today announced that the Company has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health for the development of antibodies to prevent the transmission of human papillomavirus (
Gilead Sciences Presents Data Characterizing Resistance Profile of Tenofovir DF, Investigational Agent for the Treatment of HIV: Data Presented at 5th International Workshop on HIV Drug Resistance and Treatment Strategies: Business Wire - June 5, 2001; SCOTTSDALE, Ariz.--(BUSINESS WIRE)--June 5, 2001-- Gilead Sciences , Inc. today presented in vitro data further characterizing the resistance profile of tenofovir disoproxil fumarate (tenofovir DF), the company s investigational agent in development for the potential treatment of HIV infection. The resistance profile o
Gilead Sciences Presents Data Characterizing Resistance Profile of Tenofovir DF, Investigational Agent for the Treatment of HIV: Data Presented at 5th International Workshop on HIV Drug Resistance and Treatment Strategies: Business Wire - June 5, 2001; SCOTTSDALE, Ariz.--(BUSINESS WIRE)--June 5, 2001-- Gilead Sciences , Inc. today presented in vitro data further characterizing the resistance profile of tenofovir disoproxil fumarate (tenofovir DF), the company s investigational agent in development for the potential treatment of HIV infection. The resistance profile o
Gilead Sciences Presents Data Characterizing Resistance Profile of Tenofovir DF, Investigational Agent for the Treatment of HIV: Data Presented at 5th International Workshop on HIV Drug Resistance and Treatment Strategies: Business Wire - June 5, 2001; SCOTTSDALE, Ariz.--(BUSINESS WIRE)--June 5, 2001-- Gilead Sciences , Inc. today presented in vitro data further characterizing the resistance profile of tenofovir disoproxil fumarate (tenofovir DF), the company s investigational agent in development for the potential treatment of HIV infection. The resistance profile o
The Immune Response Corporation Reports Findings From Phase II Clinical Trial of REMUNE in HIV-Infected Patients: Business Wire - June 1, 2001; CARLSBAD, Calif.--(BUSINESS WIRE)--June 1, 2001--The Immune Response Corporation (NASDAQ:IMNR) announced today that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-base
The Immune Response Corporation Reports Findings From Phase II Clinical Trial of REMUNE in HIV-Infected Patients: Business Wire - June 1, 2001; CARLSBAD, Calif.--(BUSINESS WIRE)--June 1, 2001--The Immune Response Corporation (NASDAQ:IMNR) announced today that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-base
The Immune Response Corporation Reports Findings From Phase II Clinical Trial of REMUNE in HIV-Infected Patients: Business Wire - June 1, 2001; CARLSBAD, Calif.--(BUSINESS WIRE)--June 1, 2001--The Immune Response Corporation (NASDAQ:IMNR) announced today that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-base
Stanford Researcher Addresses AIDS Crisis in Zimbabwe: Business Wire - June 1, 2001; STANFORD, Calif.--(BUSINESS WIRE)--June 1, 2001--For many years, AIDS care and treatment in Africa has long been dismissed as unfeasible -- the drug therapies too expensive, the health care infrastructure too inadequate and the infection rate too great. But a Stanford University Medical Center researcher who has spent
Stanford Researcher Addresses AIDS Crisis in Zimbabwe: Business Wire - June 1, 2001; STANFORD, Calif.--(BUSINESS WIRE)--June 1, 2001--For many years, AIDS care and treatment in Africa has long been dismissed as unfeasible -- the drug therapies too expensive, the health care infrastructure too inadequate and the infection rate too great. But a Stanford University Medical Center researcher who has spent
Stanford Researcher Addresses AIDS Crisis in Zimbabwe: Business Wire - June 1, 2001; STANFORD, Calif.--(BUSINESS WIRE)--June 1, 2001--For many years, AIDS care and treatment in Africa has long been dismissed as unfeasible -- the drug therapies too expensive, the health care infrastructure too inadequate and the infection rate too great. But a Stanford University Medical Center researcher who has spent
The Immune Response Corporation Reports Findings From Phase II Clinical Trial of REMUNE in HIV-Infected Patients: Business Wire - June 1, 2001; CARLSBAD, Calif.--(BUSINESS WIRE)--June 1, 2001--The Immune Response Corporation (NASDAQ:IMNR) announced today that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-base
The Immune Response Corporation Reports Findings From Phase II Clinical Trial of REMUNE in HIV-Infected Patients: Business Wire - June 1, 2001; CARLSBAD, Calif.--(BUSINESS WIRE)--June 1, 2001--The Immune Response Corporation (NASDAQ:IMNR) announced today that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-base
The Immune Response Corporation Reports Findings From Phase II Clinical Trial of REMUNE in HIV-Infected Patients: Business Wire - June 1, 2001; CARLSBAD, Calif.--(BUSINESS WIRE)--June 1, 2001--The Immune Response Corporation (NASDAQ:IMNR) announced today that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-base
20th Year of AIDS Marks Release of New Church-Sensitive Outreach Material: Business Wire - May 30, 2001; SAN FRANCISCO--(BW HealthWire)--May 30, 2001--Coinciding with the 20th year of AIDS, the California Department of Health Services, Office of AIDS (CDHS-OA) will announce the availability of updated, church-sensitive HIV/AIDS outreach material. They include a new interactive HIV/AIDS Quiz Card and Getting Started supple
20th Year of AIDS Marks Release of New Church-Sensitive Outreach Material: Business Wire - May 30, 2001; SAN FRANCISCO--(BW HealthWire)--May 30, 2001--Coinciding with the 20th year of AIDS, the California Department of Health Services, Office of AIDS (CDHS-OA) will announce the availability of updated, church-sensitive HIV/AIDS outreach material. They include a new interactive HIV/AIDS Quiz Card and Getting Started supple
20th Year of AIDS Marks Release of New Church-Sensitive Outreach Material: Business Wire - May 30, 2001; SAN FRANCISCO--(BW HealthWire)--May 30, 2001--Coinciding with the 20th year of AIDS, the California Department of Health Services, Office of AIDS (CDHS-OA) will announce the availability of updated, church-sensitive HIV/AIDS outreach material. They include a new interactive HIV/AIDS Quiz Card and Getting Started supple
Crompton and Biosyn Sign Licensing Agreement for Topical Microbicide Development for Prevention of AIDS: Companies Aim to Create "Effective Topical Defense Against HIV and Sexually Transmitted Diseases": Business Wire - May 23, 2001; GREENWICH, Conn. & PHILADELPHIA--(BUSINESS WIRE)--May 23, 2001-- Crompton Corporation (NYSE:CK) and Biosyn, Inc. today announced the signing of a worldwide exclusive licensing agreement for Biosyn to develop Crompton s UC781 compound as a topical microbicide targeted against the AIDS virus. There is a compelling ne
Crompton and Biosyn Sign Licensing Agreement for Topical Microbicide Development for Prevention of AIDS: Companies Aim to Create "Effective Topical Defense Against HIV and Sexually Transmitted Diseases": Business Wire - May 23, 2001; GREENWICH, Conn. & PHILADELPHIA--(BUSINESS WIRE)--May 23, 2001-- Crompton Corporation (NYSE:CK) and Biosyn, Inc. today announced the signing of a worldwide exclusive licensing agreement for Biosyn to develop Crompton s UC781 compound as a topical microbicide targeted against the AIDS virus. There is a compelling ne
Crompton and Biosyn Sign Licensing Agreement for Topical Microbicide Development for Prevention of AIDS: Companies Aim to Create "Effective Topical Defense Against HIV and Sexually Transmitted Diseases": Business Wire - May 23, 2001; GREENWICH, Conn. & PHILADELPHIA--(BUSINESS WIRE)--May 23, 2001-- Crompton Corporation (NYSE:CK) and Biosyn, Inc. today announced the signing of a worldwide exclusive licensing agreement for Biosyn to develop Crompton s UC781 compound as a topical microbicide targeted against the AIDS virus. There is a compelling ne
Hemispherx Biopharma Starts a New Strategic Treatment Intervention, STI, Clinical to Enhance Immunity Against HIV: Business Wire - May 10, 2001; PHILADELPHIA--(BUSINESS WIRE)--May 10, 2001--Hemispherx Biopharma, Inc. (AMEX: HEB; HEBws) commenced today a recently FDA authorized Phase IIb protocol designed to accelerate immunologic gains in patients receiving intense antiviral therapy for HIV disease. The objectives of the new protocol, which will enroll over 100
Hemispherx Biopharma Starts a New Strategic Treatment Intervention, STI, Clinical to Enhance Immunity Against HIV: Business Wire - May 10, 2001; PHILADELPHIA--(BUSINESS WIRE)--May 10, 2001--Hemispherx Biopharma, Inc. (AMEX: HEB; HEBws) commenced today a recently FDA authorized Phase IIb protocol designed to accelerate immunologic gains in patients receiving intense antiviral therapy for HIV disease. The objectives of the new protocol, which will enroll over 100
Hemispherx Biopharma Starts a New Strategic Treatment Intervention, STI, Clinical to Enhance Immunity Against HIV: Business Wire - May 10, 2001; PHILADELPHIA--(BUSINESS WIRE)--May 10, 2001--Hemispherx Biopharma, Inc. (AMEX: HEB; HEBws) commenced today a recently FDA authorized Phase IIb protocol designed to accelerate immunologic gains in patients receiving intense antiviral therapy for HIV disease. The objectives of the new protocol, which will enroll over 100
NY Daily News Reports on Potential of Atlantic Technology Venture's CT-3 Synthetic Derivative of Marijuana: Business Wire - May 8, 2001; NEW YORK--(BW HealthWire)--May 8, 2001--The NY Daily News reported yesterday on the potential of Atlantic Technology Ventures, Inc. s (NASDAQ:ATLC) CT-3 as a therapy that circumvents the political stigma associated with patients smoking marijuana to reduce side effects resulting from chemotherapy, arthritis, AIDS, seve
NY Daily News Reports on Potential of Atlantic Technology Venture's CT-3 Synthetic Derivative of Marijuana: Business Wire - May 8, 2001; NEW YORK--(BW HealthWire)--May 8, 2001--The NY Daily News reported yesterday on the potential of Atlantic Technology Ventures, Inc. s (NASDAQ:ATLC) CT-3 as a therapy that circumvents the political stigma associated with patients smoking marijuana to reduce side effects resulting from chemotherapy, arthritis, AIDS, seve
NY Daily News Reports on Potential of Atlantic Technology Venture's CT-3 Synthetic Derivative of Marijuana: Business Wire - May 8, 2001; NEW YORK--(BW HealthWire)--May 8, 2001--The NY Daily News reported yesterday on the potential of Atlantic Technology Ventures, Inc. s (NASDAQ:ATLC) CT-3 as a therapy that circumvents the political stigma associated with patients smoking marijuana to reduce side effects resulting from chemotherapy, arthritis, AIDS, seve
New Experimental Fertility Procedures Offer Hope For HIV Infected Men: Business Wire - May 7, 2001; SOMERVILLE, Mass.--(BW HealthWire)--May 7, 2001--New research, presented May 4 at the College of Reproductive Biology, American Association of Bioanalysts meeting, Las Vegas, NV has provided HIV infected men a potential new option for safe procreation. Dr. Hui-Zhong Yin presented results of a study of 30 HIV infected m
New Experimental Fertility Procedures Offer Hope For HIV Infected Men: Business Wire - May 7, 2001; SOMERVILLE, Mass.--(BW HealthWire)--May 7, 2001--New research, presented May 4 at the College of Reproductive Biology, American Association of Bioanalysts meeting, Las Vegas, NV has provided HIV infected men a potential new option for safe procreation. Dr. Hui-Zhong Yin presented results of a study of 30 HIV infected m
New Experimental Fertility Procedures Offer Hope For HIV Infected Men: Business Wire - May 7, 2001; SOMERVILLE, Mass.--(BW HealthWire)--May 7, 2001--New research, presented May 4 at the College of Reproductive Biology, American Association of Bioanalysts meeting, Las Vegas, NV has provided HIV infected men a potential new option for safe procreation. Dr. Hui-Zhong Yin presented results of a study of 30 HIV infected m
United Press International Publishes Science Feature On Aethlon Medical's AIDS Treatment: Business Wire - May 1, 2001; LA JOLLA, Calif.--(BW HealthWire)--May 1, 2001--Aethlon Medical (OTCBB:AEMD) announced today that the company s HIV-Hemopurifier(TM) was the subject of a feature science story that was released by United Press International (UPI) Saturday, April 28, 2001. Following is the story in its entirety and is reprinted with per
United Press International Publishes Science Feature On Aethlon Medical's AIDS Treatment: Business Wire - May 1, 2001; LA JOLLA, Calif.--(BW HealthWire)--May 1, 2001--Aethlon Medical (OTCBB:AEMD) announced today that the company s HIV-Hemopurifier(TM) was the subject of a feature science story that was released by United Press International (UPI) Saturday, April 28, 2001. Following is the story in its entirety and is reprinted with per
United Press International Publishes Science Feature On Aethlon Medical's AIDS Treatment: Business Wire - May 1, 2001; LA JOLLA, Calif.--(BW HealthWire)--May 1, 2001--Aethlon Medical (OTCBB:AEMD) announced today that the company s HIV-Hemopurifier(TM) was the subject of a feature science story that was released by United Press International (UPI) Saturday, April 28, 2001. Following is the story in its entirety and is reprinted with per
Cylex, Inc. Awarded MIPS Grant to Study HIV Immunology: Business Wire - April 20, 2001; COLUMBIA, Md.--(BUSINESS WIRE)--April 20, 2001--Cylex Inc., a Columbia, Maryland based diagnostic Company, announced it has received a Phase II Maryland Industrial Partnership (MIPS) Award in the amount of $69,218 for its project, Assay System for Measuring Immune Reconstitution. The Company is collaborating with Rober
Cylex, Inc. Awarded MIPS Grant to Study HIV Immunology: Business Wire - April 20, 2001; COLUMBIA, Md.--(BUSINESS WIRE)--April 20, 2001--Cylex Inc., a Columbia, Maryland based diagnostic Company, announced it has received a Phase II Maryland Industrial Partnership (MIPS) Award in the amount of $69,218 for its project, Assay System for Measuring Immune Reconstitution. The Company is collaborating with Rober
Cylex, Inc. Awarded MIPS Grant to Study HIV Immunology: Business Wire - April 20, 2001; COLUMBIA, Md.--(BUSINESS WIRE)--April 20, 2001--Cylex Inc., a Columbia, Maryland based diagnostic Company, announced it has received a Phase II Maryland Industrial Partnership (MIPS) Award in the amount of $69,218 for its project, Assay System for Measuring Immune Reconstitution. The Company is collaborating with Rober
Kaire Holdings Expands Senior and HIV Health Advocate Programs: Business Wire - April 18, 2001; LOS ANGELES--(BUSINESS WIRE)--April 18, 2001--Kaire Holdings, Inc. (OTCBB:KAHI) announced today that it plans to expand its senior and HIV Health Advocate Programs. The Program currently operates in Los Angeles, but the company plans to expand into Orange, San Diego and San Bernardino counties in southern California.
Kaire Holdings Expands Senior and HIV Health Advocate Programs: Business Wire - April 18, 2001; LOS ANGELES--(BUSINESS WIRE)--April 18, 2001--Kaire Holdings, Inc. (OTCBB:KAHI) announced today that it plans to expand its senior and HIV Health Advocate Programs. The Program currently operates in Los Angeles, but the company plans to expand into Orange, San Diego and San Bernardino counties in southern California.
Kaire Holdings Expands Senior and HIV Health Advocate Programs: Business Wire - April 18, 2001; LOS ANGELES--(BUSINESS WIRE)--April 18, 2001--Kaire Holdings, Inc. (OTCBB:KAHI) announced today that it plans to expand its senior and HIV Health Advocate Programs. The Program currently operates in Los Angeles, but the company plans to expand into Orange, San Diego and San Bernardino counties in southern California.
New HIV Combination Therapies Deliver Hope: Business Wire - April 13, 2001; NEWTOWN, Pa.--(BW HealthWire)--April 13, 2001--Since the onset of the AIDS epidemic 15 years ago, HIV has infected more than 47 million people globally, according to the World Health Organization . AIDS now is the fourth-leading cause of mortality worldwide. The spring 2001 issue of Scott-Levin s Pharmaceutical Quarter
New HIV Combination Therapies Deliver Hope: Business Wire - April 13, 2001; NEWTOWN, Pa.--(BW HealthWire)--April 13, 2001--Since the onset of the AIDS epidemic 15 years ago, HIV has infected more than 47 million people globally, according to the World Health Organization . AIDS now is the fourth-leading cause of mortality w